CA2558733A1 - A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual - Google Patents
A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual Download PDFInfo
- Publication number
- CA2558733A1 CA2558733A1 CA002558733A CA2558733A CA2558733A1 CA 2558733 A1 CA2558733 A1 CA 2558733A1 CA 002558733 A CA002558733 A CA 002558733A CA 2558733 A CA2558733 A CA 2558733A CA 2558733 A1 CA2558733 A1 CA 2558733A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- polypeptide
- hiv
- amino acid
- nkp44l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 228
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 177
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 137
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 44
- 229960005486 vaccine Drugs 0.000 title claims abstract description 37
- 241000700605 Viruses Species 0.000 title claims abstract description 21
- 101800001690 Transmembrane protein gp41 Proteins 0.000 title abstract description 45
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 105
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 238000000338 in vitro Methods 0.000 claims abstract description 17
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 96
- 230000014509 gene expression Effects 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 36
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 claims description 32
- 125000000539 amino acid group Chemical group 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 238000012216 screening Methods 0.000 claims description 19
- 230000001571 immunoadjuvant effect Effects 0.000 claims description 17
- 239000000568 immunological adjuvant Substances 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 15
- 102000014914 Carrier Proteins Human genes 0.000 claims description 13
- 108010078791 Carrier Proteins Proteins 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 13
- 229920001059 synthetic polymer Polymers 0.000 claims description 13
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 102000009016 Cholera Toxin Human genes 0.000 claims description 7
- 108010049048 Cholera Toxin Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 231100000765 toxin Toxicity 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 108700012359 toxins Proteins 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 4
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims description 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 238000010232 migration assay Methods 0.000 claims description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 235000017709 saponins Nutrition 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- 241000588807 Bordetella Species 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 3
- 229940001007 aluminium phosphate Drugs 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- HOPZBJPSUKPLDT-UHFFFAOYSA-N imidazo[4,5-h]quinolin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=C1 HOPZBJPSUKPLDT-UHFFFAOYSA-N 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 20
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 230000001900 immune effect Effects 0.000 abstract description 5
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 181
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 111
- 108090000623 proteins and genes Proteins 0.000 description 54
- 102000004169 proteins and genes Human genes 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 49
- 230000009089 cytolysis Effects 0.000 description 48
- 210000000822 natural killer cell Anatomy 0.000 description 45
- 230000000694 effects Effects 0.000 description 32
- 208000030507 AIDS Diseases 0.000 description 28
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 26
- 208000031886 HIV Infections Diseases 0.000 description 21
- 208000037357 HIV infectious disease Diseases 0.000 description 18
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000001472 cytotoxic effect Effects 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 206010057248 Cell death Diseases 0.000 description 11
- 101000719019 Homo sapiens Glutamyl aminopeptidase Proteins 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 241000700618 Vaccinia virus Species 0.000 description 10
- 101710090322 Truncated surface protein Proteins 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000004393 prognosis Methods 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 108010078428 env Gene Products Proteins 0.000 description 6
- 230000007813 immunodeficiency Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 5
- 102100034353 Integrase Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010041397 CD4 Antigens Proteins 0.000 description 4
- 101150050114 CTL1 gene Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- -1 poly(acrylic acid) Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 101150052401 slc44a1 gene Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101150099461 CTL2 gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010004220 Natural Cytotoxicity Triggering Receptor 2 Proteins 0.000 description 3
- 102000002751 Natural Cytotoxicity Triggering Receptor 2 Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 101150116431 Slc44a2 gene Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108700010908 HIV-1 proteins Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 2
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 101710201961 Virion infectivity factor Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GYYDPBCUIJTIBM-DYOGSRDZSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-[[(4r,5s)-4-hydroxy-3-methyl-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-methoxyoxane-3,5-diol Chemical compound O[C@@H]1[C@@H](OC)[C@@H](O)[C@@H](CO)OC1OC1[C@H]2OCC1OC(C)[C@H]2O GYYDPBCUIJTIBM-DYOGSRDZSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- GHVOAZGVLIJQGM-UHFFFAOYSA-N 2-[(1-amino-2-methyl-2-octadecylicosyl)-(2-hydroxyethyl)amino]ethanol Chemical compound C(CCCCCCCCCCCCCCCCC)C(C(N)N(CCO)CCO)(C)CCCCCCCCCCCCCCCCCC GHVOAZGVLIJQGM-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
- HJBUBXIDMQBSQW-UHFFFAOYSA-N 4-(4-diazoniophenyl)benzenediazonium Chemical compound C1=CC([N+]#N)=CC=C1C1=CC=C([N+]#N)C=C1 HJBUBXIDMQBSQW-UHFFFAOYSA-N 0.000 description 1
- 208000012124 AIDS-related disease Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920006051 Capron® Polymers 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 description 1
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
Description
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE I)E CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST ~.E TOME 1 DE 2 NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional vohxmes please contact the Canadian Patent Oi~ice.
A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an HIV virus in an individual FIELD OF THE INVENTION
s The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
to BACKGROUND OF THE INVENTION
AIDS disease, which is primarily caused by infection of individuals with a HIV retrovirus, is now the most devastating disease in the whole world, since the number of individuals which are, to date, infected with HIV viruses is estimated to about 40 millions of individuals.
is During the sole year 2001, 5 millions of individuals were infected with HIV while 3 millions of individuals have deceased in the same time.
Since the discovery of the main AIDS causative agent in 1983, namely the HIV virus, extensive efforts have been made in order to understand the mechanism of action of this virus and to develop accurate methods 2o for (i) reproducibly diagnosing the infection, as well as (ii) carrying out a prognosis of the progression of the disease in a given patient.
For surveillance purposes, the United States Centers for Disease Control (CDC) currently defines AIDS in an adult or adolescent age 13 years or older as the presence of one of 25 AIDS-indicator conditions, 2s such as KS, PCP or disseminated MAC. In children younger than 13 years, the definition of AIDS is similar to that in adolescents and adults, except that lymphoid interstitial pneumonitis and recurrent bacterial infections are included in the list of AIDS-defining conditions (CDC, 1987b). The case definition in adults and adolescents was expanded in 30 1993 to include HIV infection in an individual with a CD4~" T cell count less than 200 cells per cubic millimeter (mm3) of blood (CDC, 1992). The current surveillance definition replaced criteria published in 1987 that were based on clinical conditions and evidence of HIV infection but not on CD4~ T cell determinations (CDC, 1987).
In clinical practice, symptomatology and measurements of immune s function, notably levels of CD4+ T lymphocytes, are used to guide the treatment of HIV-infected persons HIV infects and kills CD4+ T lymphocytes in vitro, although scientists have developed immortalized T-cell lines in order to propagate HIV in the laboratory (Popovic et al., 1984; Zagury et al., 1986; Garry, l0 1989; Clark et al., 1991 ). Several mechanisms of CD4+ T cell killing have been observed in lentivirus systems in vitro and may explain the progressive loss of these cells in HIV-infected individuals (reviewed in Garry, 1989; Fauci, 1993a; Pantaleo et al., 1993a). These mechanisms include disruption of the cell membrane as HIV buds from the surface is (Leonard et al., 1988) or the intracellular accumulation of heterodisperse RNAs and unintegrated DNA (Pauza et al., 1990; Koga et al., 1988).
Evidence also suggests that intracellular complexing of CD4 and viral envelope products can result in cell killing (Hoxie et al., 1986).
In addition to these direct mechanisms of CD4+ T cell depletion, 2o indirect mechanisms may result in the death of uninfected CD4+ T cells (reviewed in Fauci, 1993a; Pantaleo et al., 1993a). Uninfected cells often fuse with infected cells, resulting in giant cells called syncytia that have been associated with the cytopathic effect of HIV in vitro (Sodroski et al., 1986; Lifson et al., 1986). Uninfected cells also may be killed when free 2s gp120, the envelope protein of H1V, binds to their surfaces, marking them for destruction by antibody-dependent cellular cytotoxicity responses (Lyerly et al., 1987). Other autoimmune phenomena may also contribute to CD4~ T cell death since HIV envelope proteins share some degree of homology with certain major histocompatibility complex type II (MHC-II) 3o molecules (Golding et al., 1989; Koenig et al., 1988).
LA PRESENTE PARTIE I)E CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST ~.E TOME 1 DE 2 NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional vohxmes please contact the Canadian Patent Oi~ice.
A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an HIV virus in an individual FIELD OF THE INVENTION
s The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
to BACKGROUND OF THE INVENTION
AIDS disease, which is primarily caused by infection of individuals with a HIV retrovirus, is now the most devastating disease in the whole world, since the number of individuals which are, to date, infected with HIV viruses is estimated to about 40 millions of individuals.
is During the sole year 2001, 5 millions of individuals were infected with HIV while 3 millions of individuals have deceased in the same time.
Since the discovery of the main AIDS causative agent in 1983, namely the HIV virus, extensive efforts have been made in order to understand the mechanism of action of this virus and to develop accurate methods 2o for (i) reproducibly diagnosing the infection, as well as (ii) carrying out a prognosis of the progression of the disease in a given patient.
For surveillance purposes, the United States Centers for Disease Control (CDC) currently defines AIDS in an adult or adolescent age 13 years or older as the presence of one of 25 AIDS-indicator conditions, 2s such as KS, PCP or disseminated MAC. In children younger than 13 years, the definition of AIDS is similar to that in adolescents and adults, except that lymphoid interstitial pneumonitis and recurrent bacterial infections are included in the list of AIDS-defining conditions (CDC, 1987b). The case definition in adults and adolescents was expanded in 30 1993 to include HIV infection in an individual with a CD4~" T cell count less than 200 cells per cubic millimeter (mm3) of blood (CDC, 1992). The current surveillance definition replaced criteria published in 1987 that were based on clinical conditions and evidence of HIV infection but not on CD4~ T cell determinations (CDC, 1987).
In clinical practice, symptomatology and measurements of immune s function, notably levels of CD4+ T lymphocytes, are used to guide the treatment of HIV-infected persons HIV infects and kills CD4+ T lymphocytes in vitro, although scientists have developed immortalized T-cell lines in order to propagate HIV in the laboratory (Popovic et al., 1984; Zagury et al., 1986; Garry, l0 1989; Clark et al., 1991 ). Several mechanisms of CD4+ T cell killing have been observed in lentivirus systems in vitro and may explain the progressive loss of these cells in HIV-infected individuals (reviewed in Garry, 1989; Fauci, 1993a; Pantaleo et al., 1993a). These mechanisms include disruption of the cell membrane as HIV buds from the surface is (Leonard et al., 1988) or the intracellular accumulation of heterodisperse RNAs and unintegrated DNA (Pauza et al., 1990; Koga et al., 1988).
Evidence also suggests that intracellular complexing of CD4 and viral envelope products can result in cell killing (Hoxie et al., 1986).
In addition to these direct mechanisms of CD4+ T cell depletion, 2o indirect mechanisms may result in the death of uninfected CD4+ T cells (reviewed in Fauci, 1993a; Pantaleo et al., 1993a). Uninfected cells often fuse with infected cells, resulting in giant cells called syncytia that have been associated with the cytopathic effect of HIV in vitro (Sodroski et al., 1986; Lifson et al., 1986). Uninfected cells also may be killed when free 2s gp120, the envelope protein of H1V, binds to their surfaces, marking them for destruction by antibody-dependent cellular cytotoxicity responses (Lyerly et al., 1987). Other autoimmune phenomena may also contribute to CD4~ T cell death since HIV envelope proteins share some degree of homology with certain major histocompatibility complex type II (MHC-II) 3o molecules (Golding et al., 1989; Koenig et al., 1988).
A number of investigators have suggested that superantigens, either encoded by HIV or derived from unrelated agents, may trigger massive stimulation and expansion of CD4+ T cells, ultimately leading to depletion or anergy of these cells (Janeway, 1991; Hugin et al., 1991 ).
s The untimely induction of a form of programmed cell death called apoptosis has been proposed as an additional mechanism for CD4+ T
cell loss in H IV infection (Ameisen and Capron, 1991; Terai et al., 1991;
Laurent-Crawford et al., 1991 ). Recent reports indicate that apoptosis occurs to a greater extent in HIV-infected individuals than in non-infected io persons, both in the peripheral blood and lymph nodes (Finkel et al., 1995; Pantaleo and Fauci, 1995b; Muro-Cacho et al., 1995).
It has also been observed that H1V infects precursors of CD4+ T
cells in the bone marrow and thymus and damages the microenvironment of these organs necessary for the optimal sustenance is and maturation of progenitor cells (Schnittman et al., 1990b; Stanley et al., 1992). These findings may help explain the lack of regeneration of the CD4+ T cell pool in patients with AIDS (Fauci, 1993a).
Recent studies have demonstrated a substantial viral burden and active viral replication in both the peripheral blood and lymphoid tissues 2o even early in HIV infection (Fox et al., 1989; Coombs et al., 1989; Ho et al., 1989; Michael ~et al., 1992; Bagnarelli et al., 1992; Pantaleo et al., 1993b; Embretson et al., 1993; Piatak et al., 1993). One group has reported that 25 percent of CD4~ T cells in the lymph nodes of HIV-infected individuals harbor HIV DNA early in the course of disease 2s (Embretson et al., 1993). Other data suggest that HIV infection is sustained by a dynamic process involving continuous rounds of new viral infection and the destruction and replacement of over 1 billion CD4~ T
cells per day (Wei et al., 1995; Ho et al., 1995).
Concerning the prognosis of progression of the disease in HIV-3o infected patients, a first current method consists of evaluating the increase in the number of HIV viruses which are present in a whole blood sample collected firom a patient, for example by performing conventional immunoassays with antibodies specifically directed against HIV proteins, and more specifically against the HIV capsid glycoprotein gp120.
A second current method for the prognosis ofi progression of AIDS
s in a patient consists of measuring the number of copies of the HIV
genome which is found in a whole blood sample collected from that patient, for example through performing a quantitative PCR amplification of the nucleic acids contained in said sample, using one or several nucleic acid primers) that specifically hybridise with the HIV genomic ~o RNA.
These two methods above are useful, since numerous studies have shown that people with high levels of HIV in their blood stream are more likely to develop new AIDS-related symptom or die than individuals with lower levels of the virus.
is A third current method for the prognosis of progression of AIDS in a patient consists of measuring the absolute CD4~ T-cell levels in whole blood samples from infected patients (HIVE patients), for example by carrying out flow cytometry from a blood sample of that patient, using a labelled antibody directed against the CD4 antigen.
2o All of these prognosis methods above can reproducibly be used but also have their respective technical limits, in relation with, for example, their biological significance as regards the evolution of the disease.
The use of antibodies fior evaluating the number of HIV viral 2s particles present in a biological sample form a patient comprise drawbacks due to the specificity of the antibodies which are used, since it is well known that the HIV structural proteins produced by distinct HIV
virus isolates significantly differ in their antigenic properties and that false negative results may thus be generated.
3o The measure of the number of copies of the H(V genome in a biological sample from a patient is indeed indicative that the provirus which has integrated within the infected individual's cell genome has entered into active replication cycles and that the disease is in active progression. However, this technique does not simultaneously reflect the patient's immune response against the virus progression.
s The measure of the CD4+ T-cell levels in a patient is also indicative of the disease progression, since the pathogenesis of acquired immunodeficiency syndrome (AIDS) is largely attribuable to the decrease in T-lymphocytes bearing the CD4 receptor (CD4+). Progressive deplefiion of CD4+ T-lymphocytes is associated with an increase of io clinical complications. Because of this association, the measurement of CD4+ T-cell levels is used to establish decision points for monitoring the relevance of treatments against AIDS. CD4~ T-lymphocyte levels are also used as prognostic indicators in patients with human immunodeficiency virus (HIV) disease.
is However, the measure of the CD4~ T-cell levels in a patient does not directly reflect the immunological status of the patient, excepted as regards the resulting immunodeficiency. Notably the measure of the CD4+ T-cell levels does not account for the status of the possible biological effectors that cause or mediate the observed CD4+ depletion, 2o and thus of the possible biological effectors that cause this observed patient's immunodeficiency.
Indeed, it may also be mentioned that a forecast of the progression of AIDS, in a given patient infected with HIV, can also be carried out through the detection of mutations occurring in the amino acid 2s sequence of known co-receptors for HIV that are expressed by the patient's cells, especially CD4+ cells, such as the CCR5 co-receptor, since it has been observed that HIV-infected people bearing a specific mutation in one of their two copies encoding the CCRS co-receptor may have a slower disease course that people with two normal copies of this 3o gene.
However, there remains a need in the art for additional methods that will allow the one skilled in the art to determine the status of progression of AIDS in patients who have been infected with a HIV virus so as to enable a more precise prognosis of the evolution of the disease, s including the occurrence of, or the evolution of, the numerous well known AIDS-related diseases, and also to enable a more precise monitoring of the therapeutical treatment which may be the more beneficial to the HIV-infected patient, once taken into account the progression status of the AIDS disease. For example, there is a need in the art for novel biological to markers which are indicative of the progression of AIDS, which should preferably be of biological relevance as regards the biology of the HIV
infection, such as, for example, novel biological markers of relevance as regards the immunological status of the patient tested.
Indeed, these novel biological markers might be used in is combination with one or several already known markers such as those cited above.
Further, there is still a need in the art for novel therapeutically useful compounds for preventing individuals from the occurrence of AIDS
upon infection with a HIV virus or, more generally, for treating patients 2o infected with a HIV virus. Particularly, in the definition of novel anti-HIV
multi-therapies or HAART ("Highly Active Anti-retroviral Therapy"), there is a need to include novel pharmaceutically active compounds that will specifically be directed against other target molecules than the HIV
protease and the HIV retrotranscriptase and which will act on targets 2s involved in distinct stages of the disease. Notably, there is a need in the art for novel compounds of pharmaceutical interest that are biologically active in HIV-infected patients wherein HIV has begun to actively replicate, especially in HIV-infected patient which are close to undergo a decrease in the number of their CD4+ T-cells and who are thus 3o susceptible to immunodeficiency, as well as in HIV-infected patients for whom the depletion of their CD4+ T-cells has already begun.
SUMMARY OF THE INVENTION
The invention is firstly directed to a polypeptide comprising the following amino acid sequence:
X~X2X3~.X5X6SWSNKSX7XgXgX~OX1~ (I), wherein X~, X2, X3, X5, X6, X~, X9, X~o, and X~~ mean, independently one from each other, any amino acid residue, X4 means any amino acid residue except A and W, and wherein X8 means any amino acid residue except E and S.
to It also relates to a pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family, which comprises an effective amount of a ligand compound which specifically binds to the polypeptide (I) in combination with at least one physiologically acceptable excipient.
is The invention also deals with in vitro methods for the screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV virus, wherein said method comprises the steps of (i) incubating a candidate compound to be tested with a polypeptide 2o as described above, (ii) assaying for the binding of the candidate compound to be tested with a polypeptide as described above.
The invention is also directed to a vaccine composition comprising a polypeptide (I) and an immunoadjuvant compound.
2s It is also directed to methods for treating HIV-infected patients that make use of the therapeutically active compounds and of the pharmaceutical compositions that are further described in the present specification.
3o DESCRIPTION OF THE FIGURES
Figure 1. Over-expression of NKp44L after treatment of_purified CD4+ T
cells with vaccinia virus expressing several HIV proteins.
Purified CD4+ T cells were infected with 20 pfu/cell of several recombinant vaccinia virus expressing HIV protein. Two days later, the s cells were washed twice, and stained with anti-NKp44L mAb (grey thick line), or with IgM isotype control (blak thin line). The cells were analyzed by flow cytometry. UI: Uninfected cells., WT : cells infected with wild type vaccinia virus. Gag, Pol, gp160, gp120, gp41, Tat, Nef : cells infected with vaccinia virus, expressing respectively Gag, Pol, gp160, gp120, io gp41, Tat, or Nef. The percentage of NKp44L expression was noted for each panel. .
Abscissa : NKp44L expression, Ordinates : Number of cells.
Figure 2. Over-expression of NKa44L after treatment of purified CD4+ T
is cells with recombinant aa160 HIV protein.
One million of cells were incubated with 5 ug/ml of control protein (Ctl; black circle), or recombinant gp160 protein (gp160-A : black triangle) (gp160-B: black square) or without protein (UT: untreated cells) during 2 days in presence of 10 U/ml 1L2.
20 ~ 2A) The cells were washed and stained with anti-NKp44L mAb and CD4 mAb or with isotype controls and analyzed by flow cytometry.
The percentage of NKp44L expression in CD4+ T cells was noted for each panel. Abscissa : CD4 expression, Ordinates : NKp44L expression.
2B) NK-lysis sensitivity of CD4+ T cells incubated with 25 recambinant gp160 HIV protein was analyzed for cytotoxic activity with activated autologous purified NK cells. NK lysis activity was perfiormed at different effetctor/target (E/T) ratios (Abscissa). Open diamonds with dotted lines: Untested cells; Closed bottoms: Control protein-treated cells; Closed triangles: gp160-A-treated cells; and closed squares:
3o gp160-B-treated cells. Ordinates : Specific NK lysis (%).
Figure 3. One pool of peptides from the HIV g,p41 protein both induced an higher sensitivity to NK Iysis and an over-expression of NKp44L.
One million of purified CD4+ T cells were treated with 5 ug/ml of pools of peptides from HIV gp41 protein (noted from A to J) or from s gp120 protein (gp120), as control. Each pool of peptides included 10 peptides, as described in Material and Methods section. The cells were incubed two days in presence-of 10 u/ml IL2, and then washed twice.
3A) NK-lysis sensitivity of CD4+ T cells incubafied with the different pools of peptides was analyzed for cytotoxic activity with io activated autologous purified NK cells. NK lysis activity was performed at different effetctor/target (E/T) ratios (Abscissa). Ordinates : Specific NK
lysis (%).
3B) The cells were stained with anti-NKp44L mAb and CD4 mAb is or with isotype controls and analyzed by flow cytometry. In this panel of figures, the results were only done for the untreated cells (none) or the cells treated with polls of peptides from gp120 or from the gp41 (polls C
and J). The percentage of NKp44L expression in CD4+ T cells was noted for each panel. For the other pools a low expression of NKp44L, ranged 2o from 0.2 to 1.3 %, was observed. Abscissa: NKp44L expression, Ordinates : CD4 expression.
Figiure 4. Analysis of each peptide from the pool C derived from HIV
g,p41 protein.
2s One million of purified CD4+ T cells were treated with 5 ug/ml of peptides from the pool C (see figure 6) (noted from C141 to 0150) or as controls the peptide gp41-E162 or the peptide gp120-87. The cells were incubed two days in presence of 10 u/ml IL2, and then washed twice.
4A) Killing pattern of CD4+ T cells incubated with the different 3o peptides were tested for their sensitivity to NK. Data are shown for an E/T ratio of 40/1 with activated autologous purified NK effector cells.
Ordinates : Specific NK lysis (%).
4B) The cells were stained with anfii-NKp44L mAb and CD4 mAb or with isotype controls and analyzed by flow cytometry. Ordinates s Expression of NKp44L.
Figure 5. Drastic role of the NH2-SWSNKS-COOH motif expressed by the qp41 HIV protein.
5A) Sequences of the peptide gp41-C147 (wild type : WT) and io two different control peptides included some modification just inside the "SWSNKS" motif (control 1 : Ctl1 ) or in all of the 15-mers sequence (control 2 : Cfil2).
One million of purified CD4+ T cells were treated with 1 ug/ml of highly purified WT peptide or with the both control peptides (Ctl1 and Ctl2). The is cells were incubed two days in presence of 10 u/ml IL2, and then washed twice.
5B) NK-lysis sensitivity of CD4+ T cells incubated with the different peptides was analyzed for cytotoxic activity with activated autologous purified NK cells. NK lysis activity was performed at different 2o effetctor/target (E/T) ratios (Abscissa). Open diamonds with dotted lines:
Untested cells; Closed bottoms: WT peptide-treated cells; Closed squares: Ctl1-peptide-treated cells, and Closed triangles: Ctl2-peptide-treated cells. Ordinates : Specific NK lysis (%).
5C) The cells were stained with anti-NKp44L mAb and CD4 mAb 2s or with isotype controls and analyzed by flow cytometry. The percentage of NKp44L expression in CD4+ T cells was noted for each panel.
Abscissa: NKp44L expression, Ordinates : CD4 expression.
Figure 6. Kinetics studies of NK lysis activity and NKp44L expression 3o after addition of the "active SWSNKS" peptide.
One million of purified CD4+ T cells were treated with 1 pg/ml of highly purified wild type (WT) peptide or with the both control peptides (Ctl1 and Ctl2) during several times ranged from 0 to 2880 min. After incubation, the cells were washed twice and then analyzed for cytotoxic s activity with activated autologous purified NK cells. NK lysis activity was performed at different effetctorlfiarget (E/T) ratios 9A). NK cytotoxic activity was performed after pretreatment of cell with 10ug/ml of anti-NK44L mAb (B). Flow cytometry analysis revealed the cell surface expression of NKp44L (A), and for the intra-cellular expression of to NKp44L (B). Open diamonds with dotted lines: Untested cells; Closed bottoms: WT peptide-treated cells; Closed squares: Ctl1-peptide-treated cells, and Closed triangles: Ctl2-peptide-treated cells; Open bottoms with dotted line : WT-peptide-treatment cells after pretreatment with anti-NKp44L mAb and Open squares with dotted line: Ctl1-peptide-treated is cells after pretreatment with anti-Nkp44L mAb.
Figure 7. Cell surface expression of NKp44L of different human cells Cell surface expression of NKp44L of K562, Jurkat, and resting PBMC. The cells were incubated with 1 pg/ml of anti-NKp44L mAb anti-2o NKp44L mAb (grey thick line) or with the IgM isotype control (black thin), and analyzed by flow cytometry. Abscissa : NKp44L expression, Ordinates : number of cells Figiure 8. Identification of #7.1, an anti-NKp44L mAb that specifically 2s inhibits NKp44-mediated NK I
(A) Cell surface expression of NCR-Ig fusion proteins. Uninfected (UI) and HIV-1-infected (Sf2) U2 cells were incubated with 10 pg/ml of NKp30-Ig (30-Ig), NKp46-Ig (46-Ig) or NKp44-Ig (44-Ig) fusion proteins (black lines) or with the Ig control (dotted lines) and analyzed by flow 3o cytometry. Frequency of NKp44-Ig expression is noted. (B) Cell surface expression of NKp44L detected with #7.1 mAb. Uninfected (UI) and HIV-1-infected (Sf2) U2 cells were incubated with 1 pglml of #7.1 mAb (black line) or with the IgM isotype control (dotted line) and analyzed by flow cytometry. (C) #7.1 mAb inhibits NKp44-Ig binding. HIV-1-infected U2 cells that had previously been stained with either 10!mg of NKp44-Ig s fusion protein (lower pane(; black line) or control NKp46-Ig fusion protein (upper panel; black line) were incubated with #7.1 mAb (gray fine) or IgM
isotype control (dotted line) for 1 !h at 4°C and washed twice in 1 %
PBS-BSA. The cells were then analyzed by flow cytometry. Percentage of cells expressing NKp44L, after NCR-Ig incubation, is noted. (D) Inhibition to of natural cytotoxicity by #7.1 mAb. Purified NK cells, cultured in the presence of 100 U/ml IL2, were analyzed for cytotoxic activity against either the uninfected U2 cells and the HIV-1-infected U2 cell line, after treatment with 101mg/ml of #7.1 mAb, at different effectorltarget cell ratios. Open circles: IgM-isotype control-treated uninfected U2 cells;
is Closed circles: #7.1-treated uninfected U2 cells. Open squares: IgM-isotype controltreated HIV-1-infected U2 cells; Closed squares: #7.1-treated HIV-1-infected U2 cells. (E) Inhibition of natural cytotoxicity by #44/8 anti-NKp44 mAb. Purified NK cells, cultured in presence of 100 U/ml IL2, were analyzed for cytotoxic activity against either the 2o uninfected U2 cells or the HIV-1-infected U2 cell line, after treatment with pg/ml of #44/8 anti-NKp44 mAb, at different effector/target cell ratios.
Open circles: IgG1-isotype control-treated uninfected U2 cells; Closed circles: #44/8 anti-NKp44 mAbtreated a ninfected U2 cells. Open squares:
IgG1-isotype control-treated HIV-1 infected U2 cells; Closed squares:
2s #44/8 anti-NKp44 mAb-treated HIV-1 infected U2 cells.
Figure 9. Critical role of the NH2-SWSNKS-COOH motif from the up41 HIV protein.
(E) NKp44L effects were inhibited with anti-gp41-C146 polyclonal 3o antibody. One million purified CD4+ T cells from two infected patients (#CG: 322 CD4+ cells/mm3 and #BT: 208 CD4+ cells/mm3) were treated overnight with several concentrations of anti-gp41-C146 antibody. The cells were stained with the anti-NKp44L mAb and analyzed by flow cytometry. (F) Inhibition of NK lysis activity in the presence of anti-gp41-C146 antibody. CD4+ T cells from #CG and #BT samples, incubated with s several concentrations of anti-gp41-C146 antibody, were then analyzed for cytotoxic activity with IL2-activated autologous purified NK cells. Open circles: Untreated cells; Closed squares, triangles, and diamonds: CD4+
T cells treated with 1, 10, and 20 mg/ml of anti-gp41-C146 antibody, respectively. Peptide C146 is a polypeptide consisting of the aminoacid to sequence of formula (II).
DETAILED DESCRIPTION OF THE INVENTION
a) Previous findings of the inventors is It has previously been found by the inventors, that a specific protein, termed NKp44L is expressed by the CD4* T-cells form HIV-infected individuals whereas this protein is not expressed by the CD4* T-cells from individuals which are not infected with HIV. The NKp44L
protein is not expressed (i) in peripheral blood mononuclear cells (PBMC) 2o from HIV-infected patients that do not express the CD3 antigen, (ii) in PBMC form HIV-infected patients that express the CD3 antigen but not the CD4 antigen, nor (iii) in PBMC from HIV-infected patients expressing the CDR antigen. Particularly, the expression level of the NKp44L protein is further enhanced in activated CD4* T-cells, such as PHA-activated 2s CD4* T-cells, from HIV-infected individuals.
Further, it has been previously found by the inventors that an increasing expression level of the NKp44L protein is correlated with the decrease in the number of CD4'~ T-cells which is observed in HIV-infected patients, thus in patients undergoing a progression of AIDS.
3o Consequently, the expression level of the NKp44L protein is indicative of the immunological status of an HIV-infected patient.
it has also been found that CD4+ T-cells from HIV-infected patients, and especially CD4+ T-cells that express the NKp44L protein, consist of specific targets for their cytolysis by Natural Killer (NK) cells, s particularly activated NK cells, and especially autologous NK cells from the same patient.
Importantly, the present inventors have shown that the NK cells of an HIV-infected individual are activafied specifically, through a non-MHC
dependent triggering mechanism, by the autologous CD4+ T-cells that to express the NKp44L protein.
Further, the expression level of the NKp44L protein consists of a novel biological marker of the state of advancement of the HIV infection endowed with a very high biological significance, since it has been shown by the inventors that NKp44L expressed by the CD4+ T-cells triggers the is autologous NK cells and activate these NK cells for specific cytolysis of the CD4+ T-cells, through a non-MHC dependent recognition of the CD4+
T-cells by the activated NK cells. In this particular context, the NKp44L
protein expressed by the CD4+ T-cells of the HIV-infected patient activate the NK cells through the specific binding of the NKp44L protein to its 2o specific receptor counterpart which is expressed at the membrane surfiace of the NK cells, namely the NKp44 receptor protein which has already been described by Cantoni et al. (1999) and by Vitale et al.
(1998).
Further, the NKp44L protein has formerly been isolated by another 2s inventive entity and this protein has already been shown to be expressed in various kinds of tumour cell lines. Still furfiher, the NKp44L expressed by certain tumour cells has been shown to be a ligand that specifically binds to the NKp44 receptor protein cited above, which receptor protein is expressed by the NK cells, including the activated NK cells. It has also 3o been formerly shown by this other inventive entity that the NKp44 receptor protein that is expressed by the activated NK cells might be responsible for at least part of the tumour cells cytolysis effected by the activated NK cells (unpublished information).
Taken together, the results obtained by the inventors have allowed them to carry out various methods which make use of the NKp44L
s protein as a novel biologically relevant marker of the disease progression for individuals that are already diagnosed as having been infected by HIV.
b~ Findings according to the invention to The inventors have now surprisingly found that a specific polypeptide, derived from the gp41 protein from HIV, markedly enhances the expression of the Nkp44L protein of sequence SEQ ID N°1, at the membrane surface of CD4+ T-cells.
The NKp44L protein is encoded by a nucleic acid of sequence is SEQ ID N°3.
It has also been determined according to the present invention that the lysis by the NK cells of the CD4+ T-cells from patients infected with HIV depends on that specific HIV polypeptide.
HIV-1 gp41 is composed of three domains, an extracellular :2o domain (ectodomain), a transmembrane domain and an intracellular domain (endodomain). The gp41 ectodomain contains three major functional regions, i.e., the fusion peptide located at the N-terminus of gp41, followed by two 4-3 heptad repeats adjacent to the N- and C
terminal portions of the gp41 ectodomain, designated NHR (N-terminal zs heptad repeat) and CHR (C-terminal heptad repeat), respectively. The N-and C-terminal repeats are also named as "HR1" and "HR2".
Both NHR and CHR regions function as essential structures required for conformational changes during the process of membrane fusion between HIV-1 and CD4*T cells.
3o Surprinsingly, the inventors have found that a short peptide, derived from the gp41 protein, which is located between the well-known HR1 and HR2 regions, induces the surface expression of NKp44L on CD4+T cells, In other words, the inventors have identified a short peptide derived from the gp41 protein of HIV, which is responsible for the s NKp44L surface expression and thus also for the lysis of CD4+ T cells by the endogenous NK cells.
These results obtained by the inventors have allowed them to carry out screening methods, which make use of a specific peptide derived from gp41 as a new target for therapeutical agents, distinct from zo the well known HR1 and HR2 regions.
Importantly, the present inventors have also shown that the protein NKp44L is expressed on tumor cell surface and that this expression of NKp44L is induced or enhanced by said short peptide derived from gp41.
Thus according to the invention, said short peptide derived from is gp41 can be used for expressing NKp44L at the surface of tumor cells and then induce their specific lysis by NK cells.
Accordingly, the invention concerns therapeutical methods, and pharmaceutical compositions, comprising a polypeptide as briefly described above, for manufacturing anti-cancer pharmaceutical 2o compositions.
In another, aspect, the inventors have found that antibodies directed against a polypeptide derived from the gp41 protein, are produced during HIV infection of an individual.
More precisely, It has been found, according to the invention a Zs statistically significant correlation between the expression level of antibodies directed against a polypeptide derived from gp41, collected from H1V-infected individuals and the level of CD4+ T cells.
It has also been found that these antibodies inhibits the cytotoxicity of NK cells towards CD4+ T cells, in patients infected by HIV.
Accordingly, the invention concerns therapeutical methods, and vaccine compositions, comprising a polypeptide as briefly described above.
It has also been found according to the invention that the level of s the antibodies described above, decreases during the progression of HIV
infection, especially as regards the development of the patient's immunodeficiency caused by the progressive depletion of his ~D4+ T
cells.
This result obtained by the inventors has allowed them to carry out io methods which make use of the level of antibodies directed against a polypeptide derived from gp41, as a novel biologically relevant m arker of the disease progression for individuals thafi are already diagnosed as having been infected by HIV.
is Polypeptides according to the invention Accordingly, an object of the invention is a polypeptide comprising the following amino acid sequence X~X2X3X4X5X6SWSNKSX7XgXgX~oX1~ (1), wherein X~, X2, X3, X5, X6, X~, X9, X~o, and X~~ mean, independently one 2o from each other, any amino acid residue, X4 means any amino acid residue except A and W, and wherein X$ means any amino acid residue except E and S.
The term "any amino acid residue" designates any amino acid residue selected from the group consisting of the following amino acids 2s A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, and V.
Said polypeptide is also referred to as a pofypeptide of fiormula (1).
The invention encompasses further polypeptides comprising the following amino acid sequence PWASNASWSNKSLDDIW (II).
In certain embodiments said polypeptide has a length of at least 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or 200 amino acid residues.
A polypeptide, as defined above, is preferably derived from the s gp41 protein and possesses at least 39, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 consecutive amino acids of gp41 protein from HIV-1 and comprises the amino acid sequence of formula (I) above.
The polypeptide of formula (I) can be produced by recombinant DNA techniques, for example on the basis of the DNA sequence of gp41 Zo protein from HIV1, by using any of a variety of expression vectors known to those of ordinary skill in the art. Expression may be achieved in any appropriate host cell fihat has been transformed or transfected v~rith an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, is and higher eukaryotic cells, such as mammalian cells and plant cells.
Preferably, the host cells employed are E, coli, yeast or a mammalian cell line such as COS or CHO. Supernatants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter.
2o Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin.
Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.
When polypeptide of formula (I) comprises less than about 100 2s amino acids, and generally less than about 50 amino acids, it can be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where 3o amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin ElmerlApplied BioSystems Division (Foster City, Calif.), and may be operated according to the manufacturer's instructions.
s Preferably, a polypeptide of formula (I) consists of the following amino acid sequence: PWASNASWSNKSLDDIW (II).
The induction of NKp44L expression on CD4+ T-cells surface induced by the polypypetide of amino acid sequence (II) is illustrated in examples 1-3 below.
io The high kinetics of the induction of the NKp44L expression at the cell surface is compatible with fihe induction of a translocation of a pre-synthesised NKp44L intracellular protein, from the cytoplasm towards the cell surface.
is Pharmaceutical compositions according to the invention Another object of the invention is a pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family, which comprises an effective amount of a ligand compound which specifically binds to the polypeptide of formula 20 (I), in combination with at least one physiologically acceptable excipient.
By "physiologically acceptable excipient or carrier" is meant solid or liquid filler, diluent or substance which may be safely used in systemic or fiopical administration. Depending on the particular route of administration, a variety of pharmaceutically acceptable carriers well 2s known in the art include solid or liquid fillers, diluents, hydrotropes, surface active agents, and encapsulating substances. The amount of carrier employed in conjunction with the F(ab)2 fragments to provide practical quantity of material per unit dose of composition.
Pharmaceutically acceptable carriers for systemic administration 3o that may be incorporated in the composition of the invention include sugar, starches, cellulose, vegetable oils, buffers, polyols and alginic acid. Specific pharmaceutically acceptable carriers are described in the following documents, all incorporated herein by reference: U.S. Pat. No.
4,401,663, Buckwalter et al. issued August 30, 1983; European Patent Application No. 089710, LaHann et al. published Sept. 28, 1983; and s European Patent Application No. 0068592, Buckwalter et al. published Jan. 5, 1983. Preferred carriers for parenteral administration include propylene glycol, pyrrolidone, ethyl oleate, aqueous ethanol, and combinations thereof.
Representative carriers include acacia, agar, alginates, io hydroxyalkylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, carrageenan, powdered cellulose, guar gum, cholesterol, gelatin, gum agar, gum arabic, gum karaya, gum ghatti, locust bean gum, octoxynol 9, oleyl alcohol, pectin, poly(acrylic acid) and its homologs, polyethylene glycol, is polyvinyl alcohol, polyacrylamide, sodium lauryl sulfate, polyethylene oxide), polyvinylpyrrolidone, glycol monostearate, propylene glycol monostearate, xanthan gum, tragacanth, sorbitan esters, stearyl alcohol, starch and its modifications. Suitable ranges vary from about 0.5% to about 1 %.
2o For formulating a pharmaceutical composition according to the invention, the one skilled in the art will advantageously refer to the last edition of the European pharmacopoeia or of the United States pharmacopoeia.
Preferably, the one skilled in the art will refer to the fourth edition 2s "2002" of the European Pharmacopoeia, or also to the edition USP 25-NF20 of the United States Pharmacopoeia.
The weight amount of therapeutically active compound that is contained in each dose of the pharmaceutical composition of the invention will depend on the molecular weight of said therapeutically 3o active compound as well as on the weight amount that is effective in blocking the cytolysis of the CD4+ T-cells by the NK cells in an HIV-infected patient.
For determining the appropriate amount of the therapeutically active compound, in a dose of a pharmaceutical composition of the s invention, the one skilled in the art firstly determines the in vitro CD4+ T-cell cytolysis inhibiting ability of various weight amounts or concentrations of said therapeutically active compound, for example by performing the screening method of the invention which are describe below, and then retain or select the given amount or concentration of said therapeutically to active compound that blocks cytolysis.
Then, the one skilled in the art transposes said retained or selected amount or concentration to the in vivo human situation, so that the concentration of said therapeutically active compound in the blood of a patient to which the pharmaceutical composition of the invention has is been administered is identical to the concentration that blocks cytolysis in vitro.
Preferably, the ligand compound consists of an antibody directed to the polypeptide according to the invention.
Preferably, the ligand compound, or the pharmaceutical 2o composition containing it, can be combined with a compound that inhibits the membrane fusion between HIV and CD4+ T cells. Such compounds are, for example, peptides derived from the HR1 or HR2 region of the gp41 protein and more precisely peptides referred to as T20, T21 or those described in US patent application 6,623,741.
~s The invention concerns also an antibody directed against a polypeptide of formula (I).
This invention is also directed to the use of a ligand compound which specifically binds to the polypeptide of formula (I), for manufacturing a pharmaceutical composition for preventing or treating a o disease linked to the infection of an individual with a virus of the HIV
family.
Additionally, The inventors have also shown that the protein NKp44L is expressed on tumor cell surface, such as Jurkat cells and K562 cells.
They have also shown that a polypeptide of formula (I) induces the s cell surface expression, of NKp44L by tumor cells, which then render these polypeptide-treated tumor cells susceptible to specific lysis by the NK cells.
Accordingly, the invention concerns methods and pharmaceutical compositions, comprising a polypeptide of formula (I), for treating cancer.
io The invention concerns a pharmaceutical composition for treating a cancer, which comprises an effective amount of an antigenic compound comprising or consisting of a polypeptide of formula (I), in combination with at least one physiologically acceptable excipient.
Preferably, the physiologically acceptable excipients used to carry is out the pharmaceutical composition described above are the same than those that are described in the first part of the specification concerning ligands of NKp44L.
The invention concerns also a pharmaceutical composition for treating a cancer, which comprises an effective amount of an antigenic 2o compound comprising or consisting of a polypeptide of formula (I), fused to a targeting cancer cells, in combination with at least one physiologically acceptable excipient.
Preferably, said compound, which targets cancer cells, consists of an antibody directed to an antigen specific of cancer, such as SCP-1, 2s NY-ESO-1, or SSX-2 specific of breast cancer, SSX-2, NY-ESO-1, or MACE-3 specific of melanoma, described in US patent 6,338,947 ; or antigens specific of renal cancers such as those described in US patent 6,440,663 ; KH-1 and N3 specific of colon cancer, described in US patent 6,238,668.
Immunoaenic and vaccine compositions according to the invention The inventors have found that antibodies directed against a polypeptide derived from the gp41 protein, i.e. the polypeptide of formula (I), are produced during HIV infection of an individual.
More precisely, It has been found, according to the invention a s statistically significant correlation between the expression level of antibodies directed the polypeptide of formula (I), collected from HIV-infected individuals and their level of CD4+ T cells.
It has also been found that these antibodies inhibits the cytotoxicity of NK cells towards CD4+ T cells, in patients infected by HIV.
to Further, the inventors have surprisingly found that antibodies screened for their capacity to inhibit CD4+ T cells NK lysis, react specifically with NKp44L on HIV-1 infected cells (example 5).
More precisely, when cells chronically infected by HIV-1 are pretreated with the antibody described above, their NK-mediated lysis is decreased sharply (Fig. 9E), and treatment of NK cells by an anti-NKp44 mAb produced the same effect (Fig. 9F).
NKp44 is a protein having the amino acid sequence SEQ !D N°2, encoded by a nucleic acid of sequence SEQ ID N°4.
It has also been found that an antibody directed against a 2o polypeptide of formula (I) above, inhibits NKp44L expression onto CD4+T
cells surface, and by the way, decreases sensitivity to NK lysis.
On the opposite, such a result is not obtain with antibodies directed against other polypeptides derived from gp41 protein, for example polypeptides T20 or T21, derived from HR1 or HR2 domains of 2s gp41.
More precisely, it has been found that NKp44L expression was substantially lower in purified CD4+ T cells from two HIV-1 infected patients that were incubated with an antibody directed to the polynucleotide (I), than in purified and then untreated cells or in those 3o treated with a control Ab. (example 6, figure 9) It has also been found that the serum from patients infected by HIV, when depleted in antibodies directed against polypeptide (I) is not able to decrease the CD4+ T cells NK lysis.
These results strongly suggest that the polypeptide of formula (I) s play a key role in inducing NKp44L expression during HIV infection and that the gp41 protein participates in the selective destruction of CD4+ T
cells by activated NK cells.
Without wishing to be bound to any particular theory, the inventors believe that HIV-1 has acquired the ability to use NK cells to disarm the io host immune system by selectively triggering CD4+T cells.
Hence, the blockage of NKp44L expression by antibodies directed against polypeptide (!) could be applied to counteract these deleterious effects.
To illustrate this hypothesis, the inventors have found that there is exists an inverse relationship between NKp44L expression at the CD4+ T
cell surface and the level of antibodies directed against the polypeptide derived from gp41, of formula (I).
Accordingly, another object of the invention is a vaccine composition comprising a polypeptide of formula (I) and an 2o immunoadjuvant compound.
A further object of the invention is an immunogenic composition comprising a polypeptide of formula (I), in combination with at least one physiologically acceptable excipient.
By "immunogenic composition" it is herein intended a substance 2s which is able fio induce an immune response in an individual, and for example to induce the production of antibodies directed against the polypeptide of formula (I).
Preferably, said immunoadjuvant compound is selected in the group consisting of Freund complete adjuvant, Freund incomplete 3o adjuvant, aluminium hydroxide, calcium phosphate, aluminium phosphate, potassium phosphate, Cholera toxin (CT) and its B subunit (CTB), toxins from Bordetella pertusssis (PT), labile toxin (LT) from Escherichia coli, monophosphoryl lipid A, CpG oligonucleotides, imidazoquinolones, oil in water emulsions, comprising squalene and synthetic copolymers, muramyl dipeptides and their derivatives, saponins s and immunostimulating complexes (ISCOMs), and dimethyldioctadecylammonium bromide or chloride (DDA).
For example, to promote a Th2-type immune response, said immunoadjuvant can be selected in the group comprising: aluminium hydroxide, aluminium phosphate, potassium phosphate, calcium io phosphate, or bacteria toxins such as Cholera toxin (CT) and its B
subunit (CTB), toxins from Bordetella pertusssis (PT), or labile toxin (LT) from Escherichia coli. When a Th1-type response is searched, said immunoadjuant can be selected in the group comprising:
monophosphoryl lipid A, CpG oligonucleotides, imidazoquinolones. To is stimulate preferably an antibody response, oil-based adjuvants such as oil in water emulsions, comprising squalene and synthetic copolymers can be used as an immunoadjuvant or also muramyl dipeptides and their derivatives. To promote a mucosal immune response, polysaccharides such as dextran, mannans, glucans, or chitosans can be used as an 2o immunoadjuvant. To enhance antibody production and stimulate T
cytotoxic lymphocytes, saponins and immunostimulating complexes (ISCOMs) can be used as an immunoadjuvant. To induce a humoral and cellular response, a Freund complete adjuvant can be used as an immunoadjuvant. To induce an inflammatory response and a high level of zs antibodies, a Freund uncomplete adjuvant can be used as an immunoadjuvant. To obtain a delayed hypersensitivity lipophilic amines such as dimethyldioctadecylammonium bromide or chloride (DDA) can be used as an immunoadjuvant.
In order to enhance the immunogenicity of the vaccine 3o composition according to the invention, the polypeptide of formula (I), can comprise from 2 to 12 peptides of formula "SWSNKS".
In particular, said antigenic polypeptide, can have the fiollowing formula (III) NH2-PepNt-[(I)"-PepX"]"-PepCt- COOH (III), wherein s - "PepNt" consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the N-terminal end of the polypeptide of formula (III);
- "[(I)"-PepXn]" consists of a polypeptide unit wherein - "(I)~" to - "(I)n" each consists of, one independently from each other, a to polypeptide of fiormula "SWSNKS", with n being an integer from 1 to 12; and - "PepX~" to "PepX"" each consists of, one independently from the other, a spacer polypeptide having an amino acid length varying from 0 to 30 amino acid residues, with n being an integer from 1 to 12;
is - n is the number of [(I)n-PepXn] polypeptide units in said polypeptide, with n being an integer firom 1 to 12; and - "PepCt" consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the C-terminal end of the polypeptide ofi formula (III).
2o Said antigenic polypeptide can be covalently linked through an amino acid residue to a carrier protein or a synthetic polymer.
In order to enhance peptide immunogenicity, the peptide of formula (I) can be covalently linked ("conjugated") to a larger molecule which serves as a carrier.
2s Attachment of the peptide to the carrier can be by one ofi several methods, including linking through a pepfiide Lys using glutaraldehyde (Reichlin, Methods Enzymol. 70: 159-165, 1980) or DCC procedures (for example, Atassi et al., Biochem. Biophys. Acta 670: 300-302, 1981 ), through a Peptide Asp or Glu using DCC (Bauminger et al., Methods 3o Enzymol 70: 151-159, 1980), through a peptide Tyr using bis-diazotized benzidine (Walter et al., Proc. Nat. Acad. Sci. USA 77: 5197-5200, 1980), through photochemical attachment sites (Parker et al., Cold Spring Harbor Symposium - Modern Aoproaches to Vaccines, Ed. Chanock &
Lerner, Cold Spring Harbor Press, New York, 1984), or through a peptide Cys (Liu et al., Biochem. 18: 690-697, 1979).
s Peptide carrier conjugates can be separated from excess free peptide by dialysis or gel filtration. The level of loading of the peptide on the carrier can be determined either using a radioactive tracer to establish the loading level in a particular procedure, or by quantitative amino acid analysis of the conjugate, in comparison with the unloaded to carrier. It is convenient, when using the latter technique, to incorporate a unique non-natural amino acid into the peptide, at the N-terminal or C-terminal side, such as Nle, which can then serve as a quantitative marker for peptide incorporation, as measured by amino acid analysis of the conjugate. This Nle can also function as a spacer between the antigenic is site and any amino acid incorporated to facilitate attachment, such as Cys, Lys, or Tyr, as described above.
Preferably, said carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin, or diphtheria toxoid.
2o In a vaccine composition according to the invention, said synthetic polymer can be a multiple branch peptide construction comprising a core matrix comprised of lysine residues.
Radially branched systems using lysine skeletons in polymers have been used by J. P. Tam [Proc. Natl. Acad. Sci. U.S.A., 85, 5409 2s 5413 (1988)] to develop antigens without the use of carriers. Those antigens were designed to generate vaccines against a variety of diseases. Specifically, antigens for generating vaccines against HIV
infection are described by Tam in PCT pafient application ser. no.
W093/03766, and in US patent Application US5,229,490.
3o The core matrix is preferably a dendritic polymer which is branched in nature, preferably with each of the branches thereof being identical. The core matrix is based on a core molecule which has at least two functional groups to which molecular branches having terminal functional groups are covalently bonded. Exemplary for use to form the core matrix is lysine. A central lysine residue is bonded to two lysine s residues, each through its carboxyl group, to one of the amino groups of the central lysine residue. This provides a molecule with four amino groups, which may be a core matrix for a structure comprising four polypeptides of formula (I). The manufacture of the above structures, has been know in the art. See, e.g., Tam et al., J. Immun. 148, 914-920 io (1992) and Wang et al., Science, 254, 285-288 (1991 ).
Additionally, spacers between said polypeptide and said carrier protein or synthetic polymer can be added. A peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds is into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1 ) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure 2o that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Qther near neutral amino acids, such as Thr and Ala may also be used in the linker 2s sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985;
Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Pat.
No. 4,935,233 and U.S. Pat. No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences 3o are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.
The invention concerns also a vaccine composition comprising a polypeptide comprising the amino acid sequence SWSNKS, said s polypeptide, being covalently linked through an amino acid residue to a carrier protein or to a synthetic polymer.
Preferably, said carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin, or diphtheria toxoid.
io The synthetic polymer can be a multiple branch peptide construction comprising a core matrix comprised of lysine residues.
Spacers between said polypeptide and said carrier protein or synthetic polymer can be introduced.
Prefrably, In the vaccine composition cited immediately above, is there are spacers between said polypeptide and said carrier protein or synthetic polymer.
This invention is also directed to the use of an antibody directed against a polypeptide of formula (I) for manufacturing a pharmaceutical composition for treating a disease linked to the infection of an individual 2o with a virus of the HIV family.
Additional compounds In a preferred embodiment, the vaccine composition according to the invention, further comprises one or more components selected from as the group consisting of surfactants, absorption promoters, water absorbing polymers, substances which inhibit enzymatic degradation, alcohol, organic solvents, oils, pH controlling agents, preservatives, osmotic pressure controlling agents, propellants, water and mixture thereof.
3o Examples of appropriate supplementary carriers include, but are not limited to, sterile water, saline, buffers, phosphate-buffered saline, buffered sodium chloride, vegetable oils, Minimum Essential Medium (MEM), MEM with HEPES buffer, etc.
Optionally, the vaccine composition of the invention may contain conventional, secondary adjuvants in varying amounts depending on the s adjuvant and the desired result. The customary amount ranges from about 0.02% to about 20% by weight, depending upon the other ingredients and desired effect.
Examples of suitable secondary adjuvants include, but are not limited to, stabilizers; emulsifiers; aluminum hydroxide; aluminum io phosphate; pH adjusters such as sodium hydroxide, hydrochloric acid, etc.; surfactants such as Tween® 80 (polysorbate 80, commercially available from Sigma Chemical Co., St. Louis, Mo.); liposomes; iscom adjuvant; synthetic glycopeptides such as muramyl dipeptides; extenders such as dextran or dextran combinations, for example, with aluminum is phosphate; carboxypolymethylene; bacterial cell walls such as mycobacterial cell wall extract; their derivatives such as Corynebacterium parvum; Propionibacterium acne; Mycobacterium bovis, for example, Bovine Calmette Guerin (BCG); vaccinia or animal poxvirus proteins;
subviral particle adjuvants such as orbivirus; cholera toxin; N,N-2o dioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine (avridine);
monophosphoryl lipid A; dimethyldioctadecylammonium bromide (DDA, commercially available from Kodak, Rochester, N.Y.); synthetics and mixtures thereof. Desirably, aluminum hydroxide is admixed with other secondary adjuvants or an immunoadjuvant such as Quil A.
as Examples of suitable stabilizers include, but are not limited to, sucrose, gelatin, peptone, digested protein extracts such as N~-Amine or NZ-Amine AS. Examples of emulsifiers include, but are not limited to, mineral oil, vegetable oil, peanut oil and other standard, metabolizable, non-toxic oils useful for injectables or intranasal vaccines compositions.
3o These adjuvants are identified herein as "secondary" merely to contrast with the above-described immunoadjuvant compounds.
Conventional preservatives can be added to the vaccine composition in effective amounts ranging from about 0.0001 % to about 0.1 % by weight. Depending on the preservative employed in the formulation, amounts below or above this range may be useful. Typical s preservatives include, for example, potassium sorbate, sodium metabisulfite, phenol, methyl paraben, propyl paraben, thimerosal, etc.
The choice of inactivated, modified or other type of vaccine composition and method of preparation of the improved vaccine composition formulation of the present invention are known or readily io determined by those of ordinary skill in the art.
When the polypeptide (I) is not covalently bound to an immunoadjuvant, in the vaccine composition acording to the invention, a pharmacologically effective amounfi of the immunoadjuvant compound described above may be given, for example orally, parenteraNy or is otherwise, concurrently with, sequentially to or shortly after the administration of the polypeptide of formula (I).
As a general rule, the vaccine composition of the present invention is conveniently administered orally, parenterally (subcutaneously, intramuscularly, intravenously, intradermally or intraperitoneally), 2o intrabuccally, intranasally, or transdermally.
In vitro screeninpr and diagnosis methods according to the invention a) screening methods 2s The inventors have surprisingly found that a specific polypeptide, derived from the gp41 protein of HIV, markedly enhances the expression of the Nkp44L protein on CD4+ T-cells surface.
The invention also concerns a first method for the in vitro screening of compounds for preventing or treating a disease linked with 3o the infection of an individual with an HIV virus, comprising the steps of (i) incubating a candidate compound to be tested with a polypeptide of formula (I), (ii) assaying for the binding of the candidate compound to be tested with a polypeptide of formula (I).
s The binding of the candidate compound to the polypeptide of formula (I) can be carried on by the one skilled in the art, for example by using a Two-hybrid system. Other means, known from the one skilled in the art can be used for the binding assays such as the use of bio sensor techniques (Edwards and Leatherbarrow (1997) or also by Szabo et al.
to (1995)), affinity chromatography, or High Throughput Screening (HTS), (Leblanc et al 2002).
The candidate compounds, which may be screened according to the screening method above, may be of any kind, including, without being limited to, natural or synthetic compounds or molecules of is biological origin such as polypeptides.
Preferably, step (ii) consists of subjecting to a gel migration assay the mixture obtained at the end of step (i) and detecting the complexes formed between the candidate compound and the polypeptide of formula 2o The gel migration assay can be carried out as known by the one skilled in the art.
The detection of the complexes formed between the complexes formed between the candidate compound and the polypeptide according to the invention can be easily observed by determining the stain position 2s (protein bands) corresponding to the proteins analysed since the apparent molecular weight of a protein changes if it is part of a complex with another protein.
On one hand, the stains (protein bands) corresponding to the proteins submitted to the gel migration assay can be detected by specific 3o antibodies for example antibodies specifically directed against a polypeptide of formula (I). One the other hand, a polypeptide of formula (I) can be tagged for an easier detection of the proteinicandidate compound on the gel. For example, the polypeptide according to the invention can be fused to GST, HA, a poly-Histidine chain, or other detectable molecules in order to facilitate the identification of the different s proteins on the gel.
The invention further concerns a second method for the in vitro screening of compounds for preventing or treating a disease linked to the infection of an individual with an HIV virus, comprising the steps of:
a) (i) bringing into contact a first CD4+ T-cell culture with a candidate io compound, and HIV virus ;
(ii) bringing into contact a second CD4+ T-cell culture with HIV virus, in the absence of said candidate compound ; and b) detecting the presence of NKp44L at the CD4+ T-cells surface issued from the culture (i) and (ii).
is The detection of the presence of NKp44L at the CD4+ T-cells surface can be carried out as known by the one skilled in the art, for instance by a cytofluorometric analysis as it is described in the part Material and methods, corresponding to the example 6.
Preferably, the method described above, comprises an additional 2o step (c) which consists of selecting positively the candidate compound as a therapeutical agent when the level of expression of NKp44L at the CD4+ T-cells surface issued from the culture (ii) is higher than the level of expression of NKp44L at the CD4+ T-cells surface issued from the culture (i).
2s The comparison of the level of expression of NKp44L at the CD4+ T-cells surface can be assessed by counting the number of CD4+
T cells expressing NKp44L on their surface, using a fluorescence activated cell sorter (FACS), as described in the corresponding Material and Methods section.
3o Alternatively, the detection of the presence of NKp44L at the CD4+ T-cells surface can be carried out indirectly, by measuring the NK
lysis activity of CD4+ T cells, as it is described in the section Material and Methods.
This particular embodiment of the step (b) of the screening method above, despite it consists of an in vitro method, has the technical s advantage to directly reflect the therapeutical potential of the candidate compound by directly evidencing the biological activity of said candidate compound, as regards preventing the CD4+ T-cells cytolysis by the activated NK cells.
The activated NK cells may consist of cells from a NK cell line, to such as the NK92 cell line described by Gong et al. (1994) or may consist of a primary culture of normal human purified NK cells.
The CD4+ T-cells that express the NKp44L protein may consist of CD4+ T-cells, eventually under the form of a cell line, that have been transfected with a vector that allow the expression by said cells of the is NKp44L protein, or may consist of CD4+ T-cells that were initially purified from a blood sample of an HIV-infected patient.
In a specific embodiment of the screening method above, the activated NK cells and the CD4+ T-cells are autologous in that they both come from the same HIV-infected patient.
2o Preferably, the cytolysis measure consists of the conventional technique wherein the CD4+ T-cells, which are the target cells, are initially rendered radioactive with 5~Cr, and wherein the cytolysis value consists of the percentage of cell lysis, as measured by the amount of 5~Cr that is released in the cell culture medium by the lysed CD4+ T-cells.
2s Most preferably, the cytolysis value is obtained by assaying the cytolytic activity of the NK cells at increasing effector (NK cells) to target (CD4~ T-cells) ratios, for example from 1:1 to 50:1 effector : target cell ratios.
Candidate compounds for use in the screening methods described 3o immediately above can be selected among the candidate compounds which binds to one or several polypeptides of formula (I).
Accordingly, the invention also concerns a method for the in vifro screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV virus, comprising the steps of (i) submitting a candidate compound to the first screening method s above, and (ii) submitting a candidate compound positively selectionned at step (i) to the second screening method described immediately above.
b Diagnosis methods of the invention ro The inventors have found that, that antibodies directed against polypeptide (I) are produced during HIV infection.
it has also been found according to the invention a statistically significant correlation between the expression level of antibodies directed against polypeptide (I) collected from HIV-infected individuals and the is level of CD4+ T cells.
it has been found according to the invention that the level of these antibodies decrease during the progression of HIV infection, especially as regards the development of the patient's immunodeficiency caused by the progressive depletion of his CD4+ T cells.
ao Besides, the inventors have found that this kind of kinetics is specific for antibodies directed against polypeptide of formula (I) and is not observed with antibodies directed against peptides T20 or T21 derived from HR1 and HR2 domains of gp41.
It flows from the experimental results obtained by the inventors as which are briefly described above that the level of antibodies directed against a polypeptide (I), contained in the serum of an individual, reveals itself to consist of an accurate biological marker of the progression status of the infection of an individual with an HIV virus. Further, the expression level said antibodies consists of a novel biological marker of the state of 3o advancement of the HIV infection endowed with a very high biological significance, since it has been shown by the inventors that the level of antibodies directed against polypeptide (I) is more important at the beginning of infection of a patient by HIV.
Accordingly, the invention also concerns a method for the in vitro assessment of the progression status of the infection of an individual with s an HIV virus, wherein said method comprises the step of detecting in a sample from said individual, antibodies directed against a polypeptide of formula (I).
As used herein an "HIV" virus consists of either an HIV-1 or an HIV-2 virus, and more particularly any virus strain or isolate of an HIV-1 or an to HIV-2 virus.
As used herein, the "assessment of the progression status" of the infection consists of raw experimental data indicative of the immunological status of the HIV-infected patient tested; Hence, as already mentioned above, there is a statistically relevant correlation is between the amount of antibodies directed against the polypeptide of formula (I) and the CD4+ T cells count.
The sole detection of antibodies directed against a polypeptide of formula (1) might nofi be sufficient for a global accurate clinical diagnosis, or prognosis, of the progression status of the disease within the patient 2o tested. Thus, the detection of antibodies directed against a polypeptide of formula (I) might be completed by, or combined with, other diagnosis or prognosis markers of the disease, for example one of the prior art markers that have previously been cited in the present specification.
The detection of antibodies directed against a polypeptide of 2s formula (I) can be achieved using known techniques such as ELISA or RIA tests.
Methods of treatment according to the invention This invention also deals with a method for preventing or for 3o treating a disease linked to the infection of an individual with a virus of the HIV family, wherein said method comprises a step of administering to a patient in need of such treatment an effective amount of an immunogenic or a vaccine composition comprising a polypeptide of formula (i) in combination with an immunoadjuvant coompound.
In a specific embodiment of the invention, said method comprises s the following steps - preparing a purified batch (HPLC, > 95%) of polypeptide comprising the aminoacid sequence (II), linked to diphteria toxoid, - Injecting diphteria toxoid alone to a first "control" group of mammals to - Injecting the polypeptide comprising the aminoacid sequence (II), linked to diphteria toxoid, to a second "test" group of mammal, Preferably, when the mammals used are of the Macaca mulatta species, they received 0,5 mg per mammal, and per injection of diphteria toxoid, linked or not, to the polypeptide cited above, followed by 3 new is injections 3, 6 or 9 weeks later, in combination with Freund's incomplete adjuvant, - infecting the two groups of mammals with SHIV33, two weeks after the last injection, with 1 ml of a dilution at 50 TCID50/ml.
-Collecting samples consisting of serum and PBMC (peripheral 20. blood mononuclear cells) at day 0, and 1 week after each injection (before infection) and then every week after infection by SHIV, -analysing the collected samples.
These analyses can comprises, without limitation, the control of the general aspect of the sample, the measurement of the amount of CD4+ T
2s cells using a FACS, the measurement of the viral load by RT-PCR, the determination of the seroconversion by detecting antibodies directed against Env protein by EIA technique, the detection of antibodies directed against polypeptide of formula (II) by ELISA.
These analyses can comprise also the study of the effects of 3o antibodies produced by said mammals on cells infected by HIV, and for example chronically infected cells. These cells are for example, U2 cells infected by HIV-sf2, Jurkat cells infected by H1V-BRU, or CD4+ T cells infected by BRU or collected from HIV infected patients.
Further, these analyses can comprise the measurement of NKp44L expression level, by FRCS, the analysis of P24 amount, by EIA, s or the analysis of NK cytotoxic activity of several strains of NK cells, such as autologous or allogenic NK92, NK3.3, or NKL cells, using a 5~Cr test as described below.
A further object of the invention consists of a method for preventing or for treating a disease linked to the infection of an individual io with a virus of the HIV family, wherein said method comprises a step of administering to a patient in need of such treatment an effective amount of an antibody directed against the polypeptide of formula (I) The invention concerns also the use of a ligand compound which specifically binds to the polypeptide of formula (I), for manufacturing a is pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family.
The invention also deals with the use of a polypeptide of formula (I), for manufacturing a vaccine composition for treating a disease linked to the infection of an individual with a virus of the HIV family.
2o The present invention is further illustrated by, without in any way being limited fio, the following examples.
EXAMPLES
A. General material and methods 2s A.1 HIV-1 infected donors.
Blood samples of 25 HIV-1-infected patients were obtained from consenting donors at Hopital Pitie-Salpetriere. Bio-clinical examinations included routine determinations of the viral load, total blood and CD4~ T
lymphocyte counts.
3o As control group, Blood samples from 20 uninfected donors were obtained by leukapheresis from the blood bank (Hopital Pitie-Salpetriere).
A.2 Cytofluorometric analysis A three-colors FACS analysis was performed on freshly harvested PBMC. Isotype-matched immunoglobulin served as the negative control s (BD). Cells were incubated 1 h at 4°C, with the appropriate cocktail of antibodies. Anti-CD3; anti-CD4; anti-CD3, anti-CD56, anti-NKp44, anti-NKp46 or anti-NKp44L mAb. Erythrocytes were lysed using the FACS
lysing solution (BD). A minimum of 20,000 leucocytes was analyzed on a FACScan, as previously described.
to To measure the expression of cell surface activation markers, PBMC were stained with PE- or FITC-conjugated anti-HLA-DR, anti-CD69, anti-CD25, or anti-CD71 (all from BD) and analyzed by FACS.
A.3 Purification of T CD4~ cells expressing NKp44L
is CD4~ T cell subset sorting was performed using the RosetteSepCD4+ enrichment kit (StemCell). CD4+ T expressing NKp44L
were positively selected by a two step magnetic separation, CD4+ T cells were incubated with 10 pglml of anti-NKp44L for 1-h at RT, followed by treatment with goat anti IgM mouse-coated Dynabeads (Dynal) at a 2o bead-to-cell ratio of 10:1 for 30 min at RT. The cell fraction purity was determined by FACS analysis.
A.4 Isolation of primary NK cells and NK cytotoxicity assays NK lines were generated from PBMC, and then purified using the 2s StemSep cell separation system and the NK cell enrichment antibody cocktail (StemCell technologies). NK purified cells were cultured in MyeloCult H5100 medium (StemCell technologies) supplemented with 100 units rhlL-2 (Boheringer). The purity of these preparations was evaluated by flow cytometry after staining with anti-CD3 (BD), anti-CD56 30 (BD), anti-NKp44, and anti-NKp46 mAbs.
The cytolytic activity was assayed in 4-h 5~Cr-release assay as previously described. Briefly, the target cells were labeled for 2-h at 37°C
with 100 pCi per 106 cells Na5~Cr (Amersham), and washed twice with culture medium. The target cells were then distributed in round-bottomed s 96-well microtiter plates (4 x 103 cells per well), and the effector cells were added at several E/T rario. The plates were incubated 4-h at 37°C.
The supernatant were then collected and S~Cr-release was measured in a gamma counted. In experiments in which Abs were included, these were added to final concentration of 20 pg/ml. The relative specific 5'Cr-to release was calculated according to conventional methods. Values for spontaneous 5~Cr-release, which are deducted in the calculation, were between 10 and 20% of the total incorporated radioactivity. The results are presented after subtraction of the nonspecific lysis obtained with control targets. Each point represents the average of triplicate values.
is The range of the triplicates was always within 5% of their mean.
A.5 Statistical analysis Correlation analyses were performed using Sperman's non-parametric rank correlation analysis. All calculations were performed 2o using the GraphPad Prism.
B. Material and Methods of the examples -6 B.1 Purification of T CD4+ cells 2s CD4+ T cell subset sorting was performed using the RosetteSepCD4+ enrichment kit (StemCell). The cell fraction purity was determined by FACS analysis.
B.2 Cytofluorometric analysis 3o A two-colors FRCS analysis was performed on purified CD4+ T
cells. Isotype-matched immunoglobulin served as the negative control (BD). Cells were incubated 1 h at 4°C, with the appropriate cocktail of antibodies. anti-CD4 or anti-NKp44L mAb. A minimum of 20,000 CD4+ T
cells was analyzed on a FACScan, as previously described. The intra-cellular expression of NKp44L was realized as previously described, s briefly, the cells were incubated in 4% PFA buffer for 20 min, then washed in stained in presence of 0.1 % saponin/PBS/1 % BSA buffer at 4°C. the cells were then analyzed by FACS.
B.3 Isolation of primary NK cells and NK cytotoxicity assays.
to NK lines were generated from PBMC, and then purified using the StemSep cell separation system and the NK cell enrichment antibody cocktail (StemCell technologies). NK purified cells were cultured in MyeloCult H5100 medium (StemCell technologies) supplemented wifih 100 units rhlL-2 (Boheringer). The purity of these preparations was 1s evaluated by flow cytometry after staining with anti-CD3 (BD), anti-CD56 (BD), anti-NKp44, and anti-NKp46 mAbs.
The cytololytic activity was assayed in 4-h 5'Cr-release assay as previously described. Briefly, the target cells were labeled for 2-h at 37°C
with 100 pCi per 106 cells Na5'Cr (Amersham), and washed twice with 2o culture medium. The target cells were then distributed in round-bottomed 96-well microtiter plates (4 x 103 cells per well), and the effector cells were added at several E/T rario. The plates were incubated 4-h at 37°C.
The supernatant were then collected and 5'Cr-release was measured in a gamma counted. In experiments in which Abs were included, these 2s were added to final concentration of 20 pg/ml. The relative specific 5'Cr-release was calculated as previously described. Values for spontaneous 5'Cr-release, which are deducted in the calculation, were between 10 and 20% of the total incorporated radioactivity. The results are presented after subtraction of the nonspecific lysis obtained with control targets.
3o Each point represents the average of triplicate values. The range of the triplicates was always within 5% of their mean.
B.4 Recombinant vaccinia virus expression HIV-1 protein.
Purified CD4+ T cells were infected with wild type vaccinia virus (WT) or with the various recombinant vaccinia virus at a multiplicity s infection of 20 PFU/cell were used as target cells. Recombinant vaccinia viruses for HIV-1-LAI Gag, Pol, Env, Nef, Tat and Vif proteins were provided by Transgene (Strasbourg, France).
B.5 Peptides and pools of peptides.
to The synthetic 15-mers peptides were purchased from Epytop (Nimes, France) or kindly provided by Agence Nationale de la Recherche sur le SIDA. All were more than 80% pure as shown by HPLC profiles.
Pools of peptides included around 10 different peptides and each peptide overlap the previous continuous peptide for 11 residues.
is B6. mAbs screened for their capacity to inhibit NK Iysis 11. Anti-NKp44 (44/8; IgG1) and anti-NKp44L mAb (#7.1; IgM) were obtained from 5-weekold BaIB/c mice immunized with the CIonaCell-HY
2o hybridoma cloning kit, according to the manufacturer's instructions (StemCell Technologies Inc.). The anti-mouse-peroxidase hybridoma screening reagent (Roche) and ELISA were used to select antibodies.
Anti-NKp44 (44/8) mAb was prepared by immunizing the mice with NKp44-Ig protein, after specific deletion of the IgG1 human Fc fragment.
2s To obtain #7.1 mAb (IgM), mice were immunized with acid-treated U2-sf2 cells. These cells were prepared as previously described (S. Sumitran-Karuppan , E. Moller, Transpl. Immunol. 4, 163, 1996.). Briefly, one million U2-Sf2 cells were washed 3 times in PBS and treated for 5 min on ice in an acid buffer prepared by mixing equal volumes of 0.263 M citric 3o acid and 0.123 M Na2HP04 containing 1 % (w/v) BSA. After three more washes, the cells were resuspended in PBS and then irradiated and injected into the mice. All hybridomas were analyzed with 51 Cr cytotoxic assays with untreated or acid-treated 721.221 cells as targets, and the specificity of the anti-NKp44 hybridoma was analyzed by ELISA with different fusion proteins. The #7.1 mAb (IgM) mAb was purified on a s mannan-binding protein (MBP) column (Pierce), after ammonium sulfate precipitation (50% saturated solution); the anti-NKp44 mAb was purified on a protein A/G column (Pierce). The purity of each purified mAb was confirmed on SDS -PAGE.
o C. RESULTS
Example 1 Effects of several HIV viral proteins on NKp44L
expression The effect of HIV viral protein on NKp44L expression was is examined using infection with recombinant vaccinia virus expressing HIV
viral protein. As shown in Figure 1, the expression of NKp44L was markedly enhanced in CD4+ T cells infected with vaccinia virus expressing the gp160 (33,9%) or the gp41 HIV Env proteins (35,6%). In contrast, neither other HIV proteins tested, like Gag, Pol, Tat, nef, vif, or 2o gp120, influenced the cell surface expression of NKp44L protein.
Furthermore, the role of the Env protein to enhance the expression of NKp44L was confirmed in a non-viral system. Purified CD4+ T cells were treated with recombinant gp160 protein provided of two different origins, and as shown in Figure 2A, these gp160 recombinant proteins influenced 2s the expression of NKp44L. Indeed, 10,7% and 9,6% of CD4+ T cells expressed NKp44L after treatment with the gp160-A and gp160-B, respectively. On the other hand, no effect was observed with untreated cells or cells incubated with a control protein. All together, these results show that the recombinant gp160 protein markedly enhances the cell 3o surface expression of NKp44L on CD4+ T-cells surface.
Example 2 aa160 induces the NK Iysis of CD4+ T cells.
Comparison of NK lysis activity from the untreated cells, the cells treated with the control protein or the cells treated with the both s recombinant gp160 proteins (Figure 2B), shows that target cell lysis was increased in the presence of CD4+ T cells cultured with recombinant gp160 protein. The use of two different types of recombinant gp160 proteins indicates that the procedure used to induce over-expression of NKp44L and increased of NK lysis activity had no influence on the io outcome of the experiments. Together, these results indicate that gp41 HIV Env protein was required for the over-expression of NKp44L
correlated with a strong increased of NK lysis activity.
Example 3 identification of the peptide motif of the ap41 Env protein is involved in the increased of NK Iysis activity, The effect of pool of overlap peptides prepared, as described in the Materials & Methods section, has been tested, to include all of the gp41 protein. CD4+ T cells were incubated with 5 pg of each pool of peptides 2o and tested against activated NK cells. As shown in Figure 3, NK lysis was increased in cells incubated with the pool of peptides named gp41 C, but not with all of the other pool of peptides. The expression of NKp44L
in purified CD4+ T cells treated with each of the pool of peptides has been tested. This receptor was only detectable in cells treated with pool 2s gp41 C, and the percentage of positive cells was 13,3%. In no instance, NKp44L was detected on the cells incubated with the other pool of peptides tested. This suggested that one or several peptide motifs included in the pool gp41 C was directly implicated in the increased of NK
lysis via the over-expression of NKp44L. Repeated experiments with all 30 of the peptides included in the pool gp41 C was then tested. As shown in Figure 4A, the NK cytotoxic activity was strongly increased in presence of the peptides gp41-C145, gp41-C146, and gp41-C147. By contrast, with the other peptides tested, the NK lysis activity remained low, closed to the background. In parallel, the expression of NKp44L was increased after pretreatment of CD4+ T cells with the peptides gp41-C145, gp41-s C146, and gp41-C147, with a percentage of positive cells varied between 22 and 16%, but not with the other peptides (less than 7% of positive cells) (Figure 4B). These results indicated that a peptide specific to gp41 Env HIV protein could increased a NK lysis activity. Additional support to this conclusion come from that the continuous peptides named gp41-io C145, gp41-C146, and gp41-C147 included a common peptide motif NH2-SWSNKS-COOH, This motif specific to the gp41 HIV-1 protein was strongly conserved. After having shown that some continuous peptides of the gp41 are some major mediators of NK lysis, it was important to assess if the peptide motif NH2-SWSNKS-COOH was directly implicated is in the NK lysis of CD4+ T cells. Preliminary experiment with this 6-mers peptide shown any increased of cell surface expression of NKp44L or NK
cytotoxic activity, suggesting that this sequence is too small or too rapidly attack by some peptidases. However, to test this hypothesis, two 15-mers peptides derived from gp41-0146 (WT) included some mutation 2o inside the NH2-SWSNKS-COOH motif (Ctl1 ) or in all of the 15-mers sequence (Ctl2) have been constructed (figure 5A). As shown in Figure 5B, the NK cytotoxic activity was strongly increased in presence of the peptide WT. By contrast, with untreated cells (none) or the treated with the both control peptides. Similar pattern was observed concerning the 2s cell surface expression of NKp44L, indeed, in cells treated with the WT
peptide, approximately 17,4% of CD4 T cells expressed this marker. By contrast, the percentage of NKp44L+ cells was less than 4% in untreated cells or cells treated by the control peptides. These results show that the NH2-SWSNKS-COOH motif included in the gp41 protein is strongly 3o implicated in the NK lysis of CD4+ T cells.
The effect of gp41 peptide is time dependant (Figure 6). NK lysis activity started after 30 min of incubation with the WT peptide and approached a maximum closed to 4-days. On the other hand, no significant effect is observed after treatment with the untreated cells or the cells treated with s the control peptides. Furthermore, the increased of NK lysis activity is strongly inhibited after pretreatment of cells with anti-NKp44L mAb, confirming that the NK activity is directly correlated with an increase of cell surface expression of NKp44L, in cells treated with the WT peptide (Figure 6C). However, kinetic study of the cell surface expression of to NKp44L revealed that this receptor was rapidly expressed at the cell surface, indeed after 10 min of treatment with WT peptide, around 10%
of CD4+ T cells expressed this protein, and the maximun of expression (approximately 30%) was obtained 4-days after treatment. The very fast cell surface expression of NKp44L suggested an absence of new is synthesis of NKp44L, and suggested that this protein was present inside the CD4+ T cells cultured with IL2. This hypothesis was confirmed by an intracellular staining of NKp44L. As show in Figure 6D, high expression of NKp44L was detectable inside the cells, and this independently of the presence of peptides.
Example 4 Cell surface expression of NKp44L of different human cells As shown on figure 7, the surface expression of NKp44L on K562, Jurkat, and resting PBMC has been tested. The cells were incubated 2s with 1 pg/ml of anti-NKp44L mAb anti-NKp44L mAb (grey thick line) or with the IgM isotype control (black thin), and analyzed by flow cytometry.
It is clearly shown that, contrary to PBMC, tumor cells, like jurkat, and K562 cells express NKp44L on their surface.
Exemple 5 Identification of #7.1, an anti-NKp44L mAb that specifically inhibits NKp44- mediated NK Iysis.
To study the related function and expression of this ligand during HIV-1 s infection, a library of mAbs screened for their capacity to inhibit NK lysis has been tested. One of them, the #7.1 mAb, revealed an epitope expressed on NKp44L. Specific staining with this mAb was found in HIV-infected U2 cells only, not in uninfected U2 cells (Fig.BB), and it yielded a level of staining similar to that of the NKp44-Ig fusion protein (compare to Fig. 8A and 8B). Inhibition of the #7.1 mAb staining by this fusion protein confirmed that #7.1 mAb specificaly interact with a NKp44 ligand (NKp44L) (Fig. 8C). A control experiment showed no effect with the NKp46-Ig fusion protein (Fig. 8C). Furthermore, when U2 cells chronically infected by the HIV-1 Sf2 strain were pretreated with the #7.1 is mAb, their NK-mediated lysis decreased sharply (as much as 40%) (Fig.BD). Treatment of NK cells by the anti-NKp44 mAb produced the same effect (Fig. SE).Note that in both series of experiments the magnitude of the lysis obtained in the presence of anti-NKp44 or 7.1 mAb was similar to that observed with uninfected cells. We obtained similar 2o results with Jurkat cells chronically infected by the HIV-1 BRU strain (data not shown). Together, these data strongly suggest that NKp44L is expressed during HIV-1 infection and that #7.1 mAb reacts specifically with NKp44L on HIV-1 infected cells.
2s Exemple 6 Critical role of the NH2-SWSNKS-COOH motif from the ~p41 HIV protein A rabbit anti-gp41-C146 peptide polyclonal Ab has been tested for its capacity of inhibition of NKp44L expression and for sensitivity to NK lysis.
Briefly, highly purified peptide (gp41-C146 peptide) (>95%) was linked to 3o the KLH and injected in several rabbits. Serum titres were determined by ELISA on PeptiPtaks. Antibodies were purified by chromatography.
NKp44L expression was substantially lower (7.8%) in purified CD4+ T
cells from two HIV-1 infected patients that were incubated with purified anti-gp41-C146 polyclonal Ab than in purified and then untreated cells s (27.2%) or in those treated with a control Ab (27.9%) (Fig. 9E). This effect v~ras confirmed by the drastic inhibition of NK activity in the presence of the anti-gp41-C146 polyclonal Ab(Fig.9F). These results strongly suggest that the gp41 NH2-SWSNKS-COOH motif plays a key role in inducing NKp44L expression during HIV infection and that the io gp41 protein participates in the selective destruction of CD4+ T cells by activated NK cells.
REFERENCES
Arneisen JC, Capron A. Cell dysfunction and depletion in AI DS: the programmed cell death hypothesis. Immunol Today 1991;12(4):102-5.
Bagnarelli P, Menzo S, Valenza A, Manzin A, et al. Molecular profile s of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol 1992;66(12):7328-35.
Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni R., 1999, NKp44, a triggering receptor involved in tumor cell lysis by activated human to natural killer cells, is a novel member of the immunoglobulin superfamily, J Exp Med 1999 Mar 1;189(5):787-96 CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19.
is . CDC. Revision of the surveillance case definition of acquired imrnunodeficiency syndrome. MMWR 1987;36:3S-15S.
Clark SJ, Saag MS, Decker WD, Campbell-Hill S, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324(14):954-60.
20 . Coombs RW, Collier AC, Allain JP, Nikora B, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321 (24):1626-31.
Edwards and Leatherbarrow, 1997, Analytical Biochemistry, 246 : 1-6.
Ernbretson J, Zapancic M, Ribas JL, Burke A, et al. Massive covert 2s infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362(6418):359-62.
Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993a;262(3136):1011-8.
. Felici F., 1991, J Mol Biol, 222 : 301-310.
Finkel TH, Tudor-Williams G, Banda NK, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature Medicine s 1995;1 (2):129-34.
Fox CH, Kotler D, Tierney A, Wilson CS, Fauci AS. Detection of HIV-1 RNA in the lamina propria of patients with AIDS and gastrointestinal disease. J Infect Dis 1989;159(3):467-71.
Garry RF. Potential mechanisms for the cytopathic properties of HIV.
1o AI DS 1989;3(11 ):683-94.
Golding H, Shearer GM, Hillman K, Lucas P, et al. Common epitope in human immunodeficiency virus I (HIV) I-GP41 and HLA class II
elicits immunosuppressive antibodies capable of contributing to immune dysfunction in HIV-infected individuals. J Clin Invest is 1989;83(4):1430-5.
Gong et al., 1994, Leukemia, vol.8 (4):652-658.
Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321 (24):1621-5.
20 . Ho DD, Neumann AU, Perelson AS, Chen W, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
Hoxie JA, Alpers JD, Rackowski JL, Huebner K, et al. Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV.
2s Science 1986;234(4780):1123-7.
Hugin AW, Vacchio MS, Morse HC III. A virus-encoded superantigen in a retrovirus-induced immunodeficiency syndrome of mice. Science 1991;252(5004):424-7.
. Janeway C. Immune recognition. Mls: makes little sense. Nature 1991;349(6309}:459-61.
Koenig S, Earl P, Powell D, Pantaleo G, et al. Group-specific, major histocompatibility complex class-I restricted cytotoxic responses to s human immunodeficiency virus I (HIV-1 ) envelope proteins by cloned peripheral blood T cells from an HIV-1 infected individual. Proc Natl Acad Sci USA 1988;85(22):8638-42.
Koga Y, Lindstrom E, Fenyo EM, Wigzell H, Mak TW. High levels of heterodisperse RNAs accumulate in T cells infected with human io immunodeficiency virus and in normal thymocytes. Proc Natl Acad Sci USA 1988;85(12):4521-5.
Kohler G. and Milstein C., 1975, Nature, 256 : 495.
Kozbor et al., 1983, Hybridoma, 2(1 ) : 7-16.
Laurent-Crawford AG, Krust B, Muller S, Riviere Y, et al. The is cytopathic effect of HIV is associated with apoptosis. Virology 1991;185(2):829-39.
Leblanc V, Delaunay V, Claude Lelong J, Gas F, Mathis G, Grassi J, May E. 2002 . Anal Biochem. 2002 Sep 15; 308(2):247-54.) 20 . Leger OJ et al., 1997, Hum Antibodies , 8(1 ) : 3-16.
Leonard R, ~agury D, Desportes I, Bernard J, et al. Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection. Proc Natl Acad Sci USA 1988;85(10):3570-4.
Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG. AIDS
2s retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science 1986;232(4754):1123-7.
Lucas A.H., 1994, In : Development and Clinical Uses of Haemophilus b Conjugate.
Lyerly HK, Matthews TJ, Langlois AJ, Bolognesi DP, Weinhold KJ.
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci USA
s 1987;84(13):4601-5.
Martineau P., Jones P., Winter G., 1998, J Mol Biol, 280(1 ) : 117-127.
Michael NL, Vahey M, Burke DS, Redfield RR. Viral DNA and mRNA
correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV
io disease. J Virol 1992;66(1 ):310-6.
Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995;154(10):5555-66.
is . Oldenburg K.R. et al., 1992, Proc. Natl. Acad. Sci. USA, 85(8) : 2444-2448.
Pantaleo G, Fauci AS. Apoptosis in HIV infection. Nature Medicine 1995b;1 (2):118-20.
Pantaleo G, Graziosi C, Demarest JF, Butini L, et al. HIV infection is 2o active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993b;362(6418):355-8.
Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993a;328(5):327-35.
2s . Parmley and Smith, 1988, Gene, 73 : 305-318.
Pauza CD, Galindo JE, Richman DD. Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodefiiciency virus type 1 infection of CEM cells. J Exp M ed 1990;172 (4):1035-42.
. Piatak M Jr, Saag MS, Yang LC, Clark SJ, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive s PCR. Science 1993;259(5102):1749-54.
Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224(4648):497-500.
Reinmann KA et al.., 1997, AIDS Res Hum Retroviruses, 13(11 ) : 933-l0 943.
. Ridder R., Scmitz R., Legay F., Gram H., 1995, Biotechnology (N Y), 13(3) : 255-260.
. Schnittman SM, Denning SM, Greenhouse JJ, Justement JS, et al.
Evidence for susceptibility of intrathymic T-cell precursors and their is progeny carrying T-cell antigen receptor phenotypes TCR alpha beta +
and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion. Proc Natl Acad Sci USA 1990b;87(19):7727-31.
Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA. Role of 2o the HTLV-111/LAV envelope in syncytium formation and cytopathicity.
Nature 1986;322(6078):470-4.
Stanley SK, Kessler SW, Justement JS, Schnittman SM, et al. CD34+
bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 1992;149(2):689-97.
2s . Szabo et al., 1995, Curr. Opinion Struct. Biol., 5(5) : 699-705.
Terai C, Kornbluth RS, Pauza CD, Richman DD, Carson DA.
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 1991;87(5):1710-5.
Valadon P. et al., 1996, J Mol Biol, 261 : 11-22.
Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A., 1998, NKp44, a novel triggering surface molecule specifically expressed by activated natural s killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis, J Exp Med 1998 Jun 15;187(12):2065-72 Wei X, Ghosh SK, Taylor ME, Johnson VA, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
to . Westerink M.A.J., 1995, Proc. Natl. Acad. Sci. USA, 92 : 4021-4025 .
Zagury D, Bernard J, Leonard R, Cheymier R, et af. Long-term cultures of HTLV-III infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986;231(4740):850-3.
is DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST L,E TOME 1 DE 2 NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional valumes please contact the Canadian Patent Office.
s The untimely induction of a form of programmed cell death called apoptosis has been proposed as an additional mechanism for CD4+ T
cell loss in H IV infection (Ameisen and Capron, 1991; Terai et al., 1991;
Laurent-Crawford et al., 1991 ). Recent reports indicate that apoptosis occurs to a greater extent in HIV-infected individuals than in non-infected io persons, both in the peripheral blood and lymph nodes (Finkel et al., 1995; Pantaleo and Fauci, 1995b; Muro-Cacho et al., 1995).
It has also been observed that H1V infects precursors of CD4+ T
cells in the bone marrow and thymus and damages the microenvironment of these organs necessary for the optimal sustenance is and maturation of progenitor cells (Schnittman et al., 1990b; Stanley et al., 1992). These findings may help explain the lack of regeneration of the CD4+ T cell pool in patients with AIDS (Fauci, 1993a).
Recent studies have demonstrated a substantial viral burden and active viral replication in both the peripheral blood and lymphoid tissues 2o even early in HIV infection (Fox et al., 1989; Coombs et al., 1989; Ho et al., 1989; Michael ~et al., 1992; Bagnarelli et al., 1992; Pantaleo et al., 1993b; Embretson et al., 1993; Piatak et al., 1993). One group has reported that 25 percent of CD4~ T cells in the lymph nodes of HIV-infected individuals harbor HIV DNA early in the course of disease 2s (Embretson et al., 1993). Other data suggest that HIV infection is sustained by a dynamic process involving continuous rounds of new viral infection and the destruction and replacement of over 1 billion CD4~ T
cells per day (Wei et al., 1995; Ho et al., 1995).
Concerning the prognosis of progression of the disease in HIV-3o infected patients, a first current method consists of evaluating the increase in the number of HIV viruses which are present in a whole blood sample collected firom a patient, for example by performing conventional immunoassays with antibodies specifically directed against HIV proteins, and more specifically against the HIV capsid glycoprotein gp120.
A second current method for the prognosis ofi progression of AIDS
s in a patient consists of measuring the number of copies of the HIV
genome which is found in a whole blood sample collected from that patient, for example through performing a quantitative PCR amplification of the nucleic acids contained in said sample, using one or several nucleic acid primers) that specifically hybridise with the HIV genomic ~o RNA.
These two methods above are useful, since numerous studies have shown that people with high levels of HIV in their blood stream are more likely to develop new AIDS-related symptom or die than individuals with lower levels of the virus.
is A third current method for the prognosis of progression of AIDS in a patient consists of measuring the absolute CD4~ T-cell levels in whole blood samples from infected patients (HIVE patients), for example by carrying out flow cytometry from a blood sample of that patient, using a labelled antibody directed against the CD4 antigen.
2o All of these prognosis methods above can reproducibly be used but also have their respective technical limits, in relation with, for example, their biological significance as regards the evolution of the disease.
The use of antibodies fior evaluating the number of HIV viral 2s particles present in a biological sample form a patient comprise drawbacks due to the specificity of the antibodies which are used, since it is well known that the HIV structural proteins produced by distinct HIV
virus isolates significantly differ in their antigenic properties and that false negative results may thus be generated.
3o The measure of the number of copies of the H(V genome in a biological sample from a patient is indeed indicative that the provirus which has integrated within the infected individual's cell genome has entered into active replication cycles and that the disease is in active progression. However, this technique does not simultaneously reflect the patient's immune response against the virus progression.
s The measure of the CD4+ T-cell levels in a patient is also indicative of the disease progression, since the pathogenesis of acquired immunodeficiency syndrome (AIDS) is largely attribuable to the decrease in T-lymphocytes bearing the CD4 receptor (CD4+). Progressive deplefiion of CD4+ T-lymphocytes is associated with an increase of io clinical complications. Because of this association, the measurement of CD4+ T-cell levels is used to establish decision points for monitoring the relevance of treatments against AIDS. CD4~ T-lymphocyte levels are also used as prognostic indicators in patients with human immunodeficiency virus (HIV) disease.
is However, the measure of the CD4~ T-cell levels in a patient does not directly reflect the immunological status of the patient, excepted as regards the resulting immunodeficiency. Notably the measure of the CD4+ T-cell levels does not account for the status of the possible biological effectors that cause or mediate the observed CD4+ depletion, 2o and thus of the possible biological effectors that cause this observed patient's immunodeficiency.
Indeed, it may also be mentioned that a forecast of the progression of AIDS, in a given patient infected with HIV, can also be carried out through the detection of mutations occurring in the amino acid 2s sequence of known co-receptors for HIV that are expressed by the patient's cells, especially CD4+ cells, such as the CCR5 co-receptor, since it has been observed that HIV-infected people bearing a specific mutation in one of their two copies encoding the CCRS co-receptor may have a slower disease course that people with two normal copies of this 3o gene.
However, there remains a need in the art for additional methods that will allow the one skilled in the art to determine the status of progression of AIDS in patients who have been infected with a HIV virus so as to enable a more precise prognosis of the evolution of the disease, s including the occurrence of, or the evolution of, the numerous well known AIDS-related diseases, and also to enable a more precise monitoring of the therapeutical treatment which may be the more beneficial to the HIV-infected patient, once taken into account the progression status of the AIDS disease. For example, there is a need in the art for novel biological to markers which are indicative of the progression of AIDS, which should preferably be of biological relevance as regards the biology of the HIV
infection, such as, for example, novel biological markers of relevance as regards the immunological status of the patient tested.
Indeed, these novel biological markers might be used in is combination with one or several already known markers such as those cited above.
Further, there is still a need in the art for novel therapeutically useful compounds for preventing individuals from the occurrence of AIDS
upon infection with a HIV virus or, more generally, for treating patients 2o infected with a HIV virus. Particularly, in the definition of novel anti-HIV
multi-therapies or HAART ("Highly Active Anti-retroviral Therapy"), there is a need to include novel pharmaceutically active compounds that will specifically be directed against other target molecules than the HIV
protease and the HIV retrotranscriptase and which will act on targets 2s involved in distinct stages of the disease. Notably, there is a need in the art for novel compounds of pharmaceutical interest that are biologically active in HIV-infected patients wherein HIV has begun to actively replicate, especially in HIV-infected patient which are close to undergo a decrease in the number of their CD4+ T-cells and who are thus 3o susceptible to immunodeficiency, as well as in HIV-infected patients for whom the depletion of their CD4+ T-cells has already begun.
SUMMARY OF THE INVENTION
The invention is firstly directed to a polypeptide comprising the following amino acid sequence:
X~X2X3~.X5X6SWSNKSX7XgXgX~OX1~ (I), wherein X~, X2, X3, X5, X6, X~, X9, X~o, and X~~ mean, independently one from each other, any amino acid residue, X4 means any amino acid residue except A and W, and wherein X8 means any amino acid residue except E and S.
to It also relates to a pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family, which comprises an effective amount of a ligand compound which specifically binds to the polypeptide (I) in combination with at least one physiologically acceptable excipient.
is The invention also deals with in vitro methods for the screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV virus, wherein said method comprises the steps of (i) incubating a candidate compound to be tested with a polypeptide 2o as described above, (ii) assaying for the binding of the candidate compound to be tested with a polypeptide as described above.
The invention is also directed to a vaccine composition comprising a polypeptide (I) and an immunoadjuvant compound.
2s It is also directed to methods for treating HIV-infected patients that make use of the therapeutically active compounds and of the pharmaceutical compositions that are further described in the present specification.
3o DESCRIPTION OF THE FIGURES
Figure 1. Over-expression of NKp44L after treatment of_purified CD4+ T
cells with vaccinia virus expressing several HIV proteins.
Purified CD4+ T cells were infected with 20 pfu/cell of several recombinant vaccinia virus expressing HIV protein. Two days later, the s cells were washed twice, and stained with anti-NKp44L mAb (grey thick line), or with IgM isotype control (blak thin line). The cells were analyzed by flow cytometry. UI: Uninfected cells., WT : cells infected with wild type vaccinia virus. Gag, Pol, gp160, gp120, gp41, Tat, Nef : cells infected with vaccinia virus, expressing respectively Gag, Pol, gp160, gp120, io gp41, Tat, or Nef. The percentage of NKp44L expression was noted for each panel. .
Abscissa : NKp44L expression, Ordinates : Number of cells.
Figure 2. Over-expression of NKa44L after treatment of purified CD4+ T
is cells with recombinant aa160 HIV protein.
One million of cells were incubated with 5 ug/ml of control protein (Ctl; black circle), or recombinant gp160 protein (gp160-A : black triangle) (gp160-B: black square) or without protein (UT: untreated cells) during 2 days in presence of 10 U/ml 1L2.
20 ~ 2A) The cells were washed and stained with anti-NKp44L mAb and CD4 mAb or with isotype controls and analyzed by flow cytometry.
The percentage of NKp44L expression in CD4+ T cells was noted for each panel. Abscissa : CD4 expression, Ordinates : NKp44L expression.
2B) NK-lysis sensitivity of CD4+ T cells incubated with 25 recambinant gp160 HIV protein was analyzed for cytotoxic activity with activated autologous purified NK cells. NK lysis activity was perfiormed at different effetctor/target (E/T) ratios (Abscissa). Open diamonds with dotted lines: Untested cells; Closed bottoms: Control protein-treated cells; Closed triangles: gp160-A-treated cells; and closed squares:
3o gp160-B-treated cells. Ordinates : Specific NK lysis (%).
Figure 3. One pool of peptides from the HIV g,p41 protein both induced an higher sensitivity to NK Iysis and an over-expression of NKp44L.
One million of purified CD4+ T cells were treated with 5 ug/ml of pools of peptides from HIV gp41 protein (noted from A to J) or from s gp120 protein (gp120), as control. Each pool of peptides included 10 peptides, as described in Material and Methods section. The cells were incubed two days in presence-of 10 u/ml IL2, and then washed twice.
3A) NK-lysis sensitivity of CD4+ T cells incubafied with the different pools of peptides was analyzed for cytotoxic activity with io activated autologous purified NK cells. NK lysis activity was performed at different effetctor/target (E/T) ratios (Abscissa). Ordinates : Specific NK
lysis (%).
3B) The cells were stained with anti-NKp44L mAb and CD4 mAb is or with isotype controls and analyzed by flow cytometry. In this panel of figures, the results were only done for the untreated cells (none) or the cells treated with polls of peptides from gp120 or from the gp41 (polls C
and J). The percentage of NKp44L expression in CD4+ T cells was noted for each panel. For the other pools a low expression of NKp44L, ranged 2o from 0.2 to 1.3 %, was observed. Abscissa: NKp44L expression, Ordinates : CD4 expression.
Figiure 4. Analysis of each peptide from the pool C derived from HIV
g,p41 protein.
2s One million of purified CD4+ T cells were treated with 5 ug/ml of peptides from the pool C (see figure 6) (noted from C141 to 0150) or as controls the peptide gp41-E162 or the peptide gp120-87. The cells were incubed two days in presence of 10 u/ml IL2, and then washed twice.
4A) Killing pattern of CD4+ T cells incubated with the different 3o peptides were tested for their sensitivity to NK. Data are shown for an E/T ratio of 40/1 with activated autologous purified NK effector cells.
Ordinates : Specific NK lysis (%).
4B) The cells were stained with anfii-NKp44L mAb and CD4 mAb or with isotype controls and analyzed by flow cytometry. Ordinates s Expression of NKp44L.
Figure 5. Drastic role of the NH2-SWSNKS-COOH motif expressed by the qp41 HIV protein.
5A) Sequences of the peptide gp41-C147 (wild type : WT) and io two different control peptides included some modification just inside the "SWSNKS" motif (control 1 : Ctl1 ) or in all of the 15-mers sequence (control 2 : Cfil2).
One million of purified CD4+ T cells were treated with 1 ug/ml of highly purified WT peptide or with the both control peptides (Ctl1 and Ctl2). The is cells were incubed two days in presence of 10 u/ml IL2, and then washed twice.
5B) NK-lysis sensitivity of CD4+ T cells incubated with the different peptides was analyzed for cytotoxic activity with activated autologous purified NK cells. NK lysis activity was performed at different 2o effetctor/target (E/T) ratios (Abscissa). Open diamonds with dotted lines:
Untested cells; Closed bottoms: WT peptide-treated cells; Closed squares: Ctl1-peptide-treated cells, and Closed triangles: Ctl2-peptide-treated cells. Ordinates : Specific NK lysis (%).
5C) The cells were stained with anti-NKp44L mAb and CD4 mAb 2s or with isotype controls and analyzed by flow cytometry. The percentage of NKp44L expression in CD4+ T cells was noted for each panel.
Abscissa: NKp44L expression, Ordinates : CD4 expression.
Figure 6. Kinetics studies of NK lysis activity and NKp44L expression 3o after addition of the "active SWSNKS" peptide.
One million of purified CD4+ T cells were treated with 1 pg/ml of highly purified wild type (WT) peptide or with the both control peptides (Ctl1 and Ctl2) during several times ranged from 0 to 2880 min. After incubation, the cells were washed twice and then analyzed for cytotoxic s activity with activated autologous purified NK cells. NK lysis activity was performed at different effetctorlfiarget (E/T) ratios 9A). NK cytotoxic activity was performed after pretreatment of cell with 10ug/ml of anti-NK44L mAb (B). Flow cytometry analysis revealed the cell surface expression of NKp44L (A), and for the intra-cellular expression of to NKp44L (B). Open diamonds with dotted lines: Untested cells; Closed bottoms: WT peptide-treated cells; Closed squares: Ctl1-peptide-treated cells, and Closed triangles: Ctl2-peptide-treated cells; Open bottoms with dotted line : WT-peptide-treatment cells after pretreatment with anti-NKp44L mAb and Open squares with dotted line: Ctl1-peptide-treated is cells after pretreatment with anti-Nkp44L mAb.
Figure 7. Cell surface expression of NKp44L of different human cells Cell surface expression of NKp44L of K562, Jurkat, and resting PBMC. The cells were incubated with 1 pg/ml of anti-NKp44L mAb anti-2o NKp44L mAb (grey thick line) or with the IgM isotype control (black thin), and analyzed by flow cytometry. Abscissa : NKp44L expression, Ordinates : number of cells Figiure 8. Identification of #7.1, an anti-NKp44L mAb that specifically 2s inhibits NKp44-mediated NK I
(A) Cell surface expression of NCR-Ig fusion proteins. Uninfected (UI) and HIV-1-infected (Sf2) U2 cells were incubated with 10 pg/ml of NKp30-Ig (30-Ig), NKp46-Ig (46-Ig) or NKp44-Ig (44-Ig) fusion proteins (black lines) or with the Ig control (dotted lines) and analyzed by flow 3o cytometry. Frequency of NKp44-Ig expression is noted. (B) Cell surface expression of NKp44L detected with #7.1 mAb. Uninfected (UI) and HIV-1-infected (Sf2) U2 cells were incubated with 1 pglml of #7.1 mAb (black line) or with the IgM isotype control (dotted line) and analyzed by flow cytometry. (C) #7.1 mAb inhibits NKp44-Ig binding. HIV-1-infected U2 cells that had previously been stained with either 10!mg of NKp44-Ig s fusion protein (lower pane(; black line) or control NKp46-Ig fusion protein (upper panel; black line) were incubated with #7.1 mAb (gray fine) or IgM
isotype control (dotted line) for 1 !h at 4°C and washed twice in 1 %
PBS-BSA. The cells were then analyzed by flow cytometry. Percentage of cells expressing NKp44L, after NCR-Ig incubation, is noted. (D) Inhibition to of natural cytotoxicity by #7.1 mAb. Purified NK cells, cultured in the presence of 100 U/ml IL2, were analyzed for cytotoxic activity against either the uninfected U2 cells and the HIV-1-infected U2 cell line, after treatment with 101mg/ml of #7.1 mAb, at different effectorltarget cell ratios. Open circles: IgM-isotype control-treated uninfected U2 cells;
is Closed circles: #7.1-treated uninfected U2 cells. Open squares: IgM-isotype controltreated HIV-1-infected U2 cells; Closed squares: #7.1-treated HIV-1-infected U2 cells. (E) Inhibition of natural cytotoxicity by #44/8 anti-NKp44 mAb. Purified NK cells, cultured in presence of 100 U/ml IL2, were analyzed for cytotoxic activity against either the 2o uninfected U2 cells or the HIV-1-infected U2 cell line, after treatment with pg/ml of #44/8 anti-NKp44 mAb, at different effector/target cell ratios.
Open circles: IgG1-isotype control-treated uninfected U2 cells; Closed circles: #44/8 anti-NKp44 mAbtreated a ninfected U2 cells. Open squares:
IgG1-isotype control-treated HIV-1 infected U2 cells; Closed squares:
2s #44/8 anti-NKp44 mAb-treated HIV-1 infected U2 cells.
Figure 9. Critical role of the NH2-SWSNKS-COOH motif from the up41 HIV protein.
(E) NKp44L effects were inhibited with anti-gp41-C146 polyclonal 3o antibody. One million purified CD4+ T cells from two infected patients (#CG: 322 CD4+ cells/mm3 and #BT: 208 CD4+ cells/mm3) were treated overnight with several concentrations of anti-gp41-C146 antibody. The cells were stained with the anti-NKp44L mAb and analyzed by flow cytometry. (F) Inhibition of NK lysis activity in the presence of anti-gp41-C146 antibody. CD4+ T cells from #CG and #BT samples, incubated with s several concentrations of anti-gp41-C146 antibody, were then analyzed for cytotoxic activity with IL2-activated autologous purified NK cells. Open circles: Untreated cells; Closed squares, triangles, and diamonds: CD4+
T cells treated with 1, 10, and 20 mg/ml of anti-gp41-C146 antibody, respectively. Peptide C146 is a polypeptide consisting of the aminoacid to sequence of formula (II).
DETAILED DESCRIPTION OF THE INVENTION
a) Previous findings of the inventors is It has previously been found by the inventors, that a specific protein, termed NKp44L is expressed by the CD4* T-cells form HIV-infected individuals whereas this protein is not expressed by the CD4* T-cells from individuals which are not infected with HIV. The NKp44L
protein is not expressed (i) in peripheral blood mononuclear cells (PBMC) 2o from HIV-infected patients that do not express the CD3 antigen, (ii) in PBMC form HIV-infected patients that express the CD3 antigen but not the CD4 antigen, nor (iii) in PBMC from HIV-infected patients expressing the CDR antigen. Particularly, the expression level of the NKp44L protein is further enhanced in activated CD4* T-cells, such as PHA-activated 2s CD4* T-cells, from HIV-infected individuals.
Further, it has been previously found by the inventors that an increasing expression level of the NKp44L protein is correlated with the decrease in the number of CD4'~ T-cells which is observed in HIV-infected patients, thus in patients undergoing a progression of AIDS.
3o Consequently, the expression level of the NKp44L protein is indicative of the immunological status of an HIV-infected patient.
it has also been found that CD4+ T-cells from HIV-infected patients, and especially CD4+ T-cells that express the NKp44L protein, consist of specific targets for their cytolysis by Natural Killer (NK) cells, s particularly activated NK cells, and especially autologous NK cells from the same patient.
Importantly, the present inventors have shown that the NK cells of an HIV-infected individual are activafied specifically, through a non-MHC
dependent triggering mechanism, by the autologous CD4+ T-cells that to express the NKp44L protein.
Further, the expression level of the NKp44L protein consists of a novel biological marker of the state of advancement of the HIV infection endowed with a very high biological significance, since it has been shown by the inventors that NKp44L expressed by the CD4+ T-cells triggers the is autologous NK cells and activate these NK cells for specific cytolysis of the CD4+ T-cells, through a non-MHC dependent recognition of the CD4+
T-cells by the activated NK cells. In this particular context, the NKp44L
protein expressed by the CD4+ T-cells of the HIV-infected patient activate the NK cells through the specific binding of the NKp44L protein to its 2o specific receptor counterpart which is expressed at the membrane surfiace of the NK cells, namely the NKp44 receptor protein which has already been described by Cantoni et al. (1999) and by Vitale et al.
(1998).
Further, the NKp44L protein has formerly been isolated by another 2s inventive entity and this protein has already been shown to be expressed in various kinds of tumour cell lines. Still furfiher, the NKp44L expressed by certain tumour cells has been shown to be a ligand that specifically binds to the NKp44 receptor protein cited above, which receptor protein is expressed by the NK cells, including the activated NK cells. It has also 3o been formerly shown by this other inventive entity that the NKp44 receptor protein that is expressed by the activated NK cells might be responsible for at least part of the tumour cells cytolysis effected by the activated NK cells (unpublished information).
Taken together, the results obtained by the inventors have allowed them to carry out various methods which make use of the NKp44L
s protein as a novel biologically relevant marker of the disease progression for individuals that are already diagnosed as having been infected by HIV.
b~ Findings according to the invention to The inventors have now surprisingly found that a specific polypeptide, derived from the gp41 protein from HIV, markedly enhances the expression of the Nkp44L protein of sequence SEQ ID N°1, at the membrane surface of CD4+ T-cells.
The NKp44L protein is encoded by a nucleic acid of sequence is SEQ ID N°3.
It has also been determined according to the present invention that the lysis by the NK cells of the CD4+ T-cells from patients infected with HIV depends on that specific HIV polypeptide.
HIV-1 gp41 is composed of three domains, an extracellular :2o domain (ectodomain), a transmembrane domain and an intracellular domain (endodomain). The gp41 ectodomain contains three major functional regions, i.e., the fusion peptide located at the N-terminus of gp41, followed by two 4-3 heptad repeats adjacent to the N- and C
terminal portions of the gp41 ectodomain, designated NHR (N-terminal zs heptad repeat) and CHR (C-terminal heptad repeat), respectively. The N-and C-terminal repeats are also named as "HR1" and "HR2".
Both NHR and CHR regions function as essential structures required for conformational changes during the process of membrane fusion between HIV-1 and CD4*T cells.
3o Surprinsingly, the inventors have found that a short peptide, derived from the gp41 protein, which is located between the well-known HR1 and HR2 regions, induces the surface expression of NKp44L on CD4+T cells, In other words, the inventors have identified a short peptide derived from the gp41 protein of HIV, which is responsible for the s NKp44L surface expression and thus also for the lysis of CD4+ T cells by the endogenous NK cells.
These results obtained by the inventors have allowed them to carry out screening methods, which make use of a specific peptide derived from gp41 as a new target for therapeutical agents, distinct from zo the well known HR1 and HR2 regions.
Importantly, the present inventors have also shown that the protein NKp44L is expressed on tumor cell surface and that this expression of NKp44L is induced or enhanced by said short peptide derived from gp41.
Thus according to the invention, said short peptide derived from is gp41 can be used for expressing NKp44L at the surface of tumor cells and then induce their specific lysis by NK cells.
Accordingly, the invention concerns therapeutical methods, and pharmaceutical compositions, comprising a polypeptide as briefly described above, for manufacturing anti-cancer pharmaceutical 2o compositions.
In another, aspect, the inventors have found that antibodies directed against a polypeptide derived from the gp41 protein, are produced during HIV infection of an individual.
More precisely, It has been found, according to the invention a Zs statistically significant correlation between the expression level of antibodies directed against a polypeptide derived from gp41, collected from H1V-infected individuals and the level of CD4+ T cells.
It has also been found that these antibodies inhibits the cytotoxicity of NK cells towards CD4+ T cells, in patients infected by HIV.
Accordingly, the invention concerns therapeutical methods, and vaccine compositions, comprising a polypeptide as briefly described above.
It has also been found according to the invention that the level of s the antibodies described above, decreases during the progression of HIV
infection, especially as regards the development of the patient's immunodeficiency caused by the progressive depletion of his ~D4+ T
cells.
This result obtained by the inventors has allowed them to carry out io methods which make use of the level of antibodies directed against a polypeptide derived from gp41, as a novel biologically relevant m arker of the disease progression for individuals thafi are already diagnosed as having been infected by HIV.
is Polypeptides according to the invention Accordingly, an object of the invention is a polypeptide comprising the following amino acid sequence X~X2X3X4X5X6SWSNKSX7XgXgX~oX1~ (1), wherein X~, X2, X3, X5, X6, X~, X9, X~o, and X~~ mean, independently one 2o from each other, any amino acid residue, X4 means any amino acid residue except A and W, and wherein X$ means any amino acid residue except E and S.
The term "any amino acid residue" designates any amino acid residue selected from the group consisting of the following amino acids 2s A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, and V.
Said polypeptide is also referred to as a pofypeptide of fiormula (1).
The invention encompasses further polypeptides comprising the following amino acid sequence PWASNASWSNKSLDDIW (II).
In certain embodiments said polypeptide has a length of at least 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or 200 amino acid residues.
A polypeptide, as defined above, is preferably derived from the s gp41 protein and possesses at least 39, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 consecutive amino acids of gp41 protein from HIV-1 and comprises the amino acid sequence of formula (I) above.
The polypeptide of formula (I) can be produced by recombinant DNA techniques, for example on the basis of the DNA sequence of gp41 Zo protein from HIV1, by using any of a variety of expression vectors known to those of ordinary skill in the art. Expression may be achieved in any appropriate host cell fihat has been transformed or transfected v~rith an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, is and higher eukaryotic cells, such as mammalian cells and plant cells.
Preferably, the host cells employed are E, coli, yeast or a mammalian cell line such as COS or CHO. Supernatants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter.
2o Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin.
Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.
When polypeptide of formula (I) comprises less than about 100 2s amino acids, and generally less than about 50 amino acids, it can be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where 3o amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin ElmerlApplied BioSystems Division (Foster City, Calif.), and may be operated according to the manufacturer's instructions.
s Preferably, a polypeptide of formula (I) consists of the following amino acid sequence: PWASNASWSNKSLDDIW (II).
The induction of NKp44L expression on CD4+ T-cells surface induced by the polypypetide of amino acid sequence (II) is illustrated in examples 1-3 below.
io The high kinetics of the induction of the NKp44L expression at the cell surface is compatible with fihe induction of a translocation of a pre-synthesised NKp44L intracellular protein, from the cytoplasm towards the cell surface.
is Pharmaceutical compositions according to the invention Another object of the invention is a pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family, which comprises an effective amount of a ligand compound which specifically binds to the polypeptide of formula 20 (I), in combination with at least one physiologically acceptable excipient.
By "physiologically acceptable excipient or carrier" is meant solid or liquid filler, diluent or substance which may be safely used in systemic or fiopical administration. Depending on the particular route of administration, a variety of pharmaceutically acceptable carriers well 2s known in the art include solid or liquid fillers, diluents, hydrotropes, surface active agents, and encapsulating substances. The amount of carrier employed in conjunction with the F(ab)2 fragments to provide practical quantity of material per unit dose of composition.
Pharmaceutically acceptable carriers for systemic administration 3o that may be incorporated in the composition of the invention include sugar, starches, cellulose, vegetable oils, buffers, polyols and alginic acid. Specific pharmaceutically acceptable carriers are described in the following documents, all incorporated herein by reference: U.S. Pat. No.
4,401,663, Buckwalter et al. issued August 30, 1983; European Patent Application No. 089710, LaHann et al. published Sept. 28, 1983; and s European Patent Application No. 0068592, Buckwalter et al. published Jan. 5, 1983. Preferred carriers for parenteral administration include propylene glycol, pyrrolidone, ethyl oleate, aqueous ethanol, and combinations thereof.
Representative carriers include acacia, agar, alginates, io hydroxyalkylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, carrageenan, powdered cellulose, guar gum, cholesterol, gelatin, gum agar, gum arabic, gum karaya, gum ghatti, locust bean gum, octoxynol 9, oleyl alcohol, pectin, poly(acrylic acid) and its homologs, polyethylene glycol, is polyvinyl alcohol, polyacrylamide, sodium lauryl sulfate, polyethylene oxide), polyvinylpyrrolidone, glycol monostearate, propylene glycol monostearate, xanthan gum, tragacanth, sorbitan esters, stearyl alcohol, starch and its modifications. Suitable ranges vary from about 0.5% to about 1 %.
2o For formulating a pharmaceutical composition according to the invention, the one skilled in the art will advantageously refer to the last edition of the European pharmacopoeia or of the United States pharmacopoeia.
Preferably, the one skilled in the art will refer to the fourth edition 2s "2002" of the European Pharmacopoeia, or also to the edition USP 25-NF20 of the United States Pharmacopoeia.
The weight amount of therapeutically active compound that is contained in each dose of the pharmaceutical composition of the invention will depend on the molecular weight of said therapeutically 3o active compound as well as on the weight amount that is effective in blocking the cytolysis of the CD4+ T-cells by the NK cells in an HIV-infected patient.
For determining the appropriate amount of the therapeutically active compound, in a dose of a pharmaceutical composition of the s invention, the one skilled in the art firstly determines the in vitro CD4+ T-cell cytolysis inhibiting ability of various weight amounts or concentrations of said therapeutically active compound, for example by performing the screening method of the invention which are describe below, and then retain or select the given amount or concentration of said therapeutically to active compound that blocks cytolysis.
Then, the one skilled in the art transposes said retained or selected amount or concentration to the in vivo human situation, so that the concentration of said therapeutically active compound in the blood of a patient to which the pharmaceutical composition of the invention has is been administered is identical to the concentration that blocks cytolysis in vitro.
Preferably, the ligand compound consists of an antibody directed to the polypeptide according to the invention.
Preferably, the ligand compound, or the pharmaceutical 2o composition containing it, can be combined with a compound that inhibits the membrane fusion between HIV and CD4+ T cells. Such compounds are, for example, peptides derived from the HR1 or HR2 region of the gp41 protein and more precisely peptides referred to as T20, T21 or those described in US patent application 6,623,741.
~s The invention concerns also an antibody directed against a polypeptide of formula (I).
This invention is also directed to the use of a ligand compound which specifically binds to the polypeptide of formula (I), for manufacturing a pharmaceutical composition for preventing or treating a o disease linked to the infection of an individual with a virus of the HIV
family.
Additionally, The inventors have also shown that the protein NKp44L is expressed on tumor cell surface, such as Jurkat cells and K562 cells.
They have also shown that a polypeptide of formula (I) induces the s cell surface expression, of NKp44L by tumor cells, which then render these polypeptide-treated tumor cells susceptible to specific lysis by the NK cells.
Accordingly, the invention concerns methods and pharmaceutical compositions, comprising a polypeptide of formula (I), for treating cancer.
io The invention concerns a pharmaceutical composition for treating a cancer, which comprises an effective amount of an antigenic compound comprising or consisting of a polypeptide of formula (I), in combination with at least one physiologically acceptable excipient.
Preferably, the physiologically acceptable excipients used to carry is out the pharmaceutical composition described above are the same than those that are described in the first part of the specification concerning ligands of NKp44L.
The invention concerns also a pharmaceutical composition for treating a cancer, which comprises an effective amount of an antigenic 2o compound comprising or consisting of a polypeptide of formula (I), fused to a targeting cancer cells, in combination with at least one physiologically acceptable excipient.
Preferably, said compound, which targets cancer cells, consists of an antibody directed to an antigen specific of cancer, such as SCP-1, 2s NY-ESO-1, or SSX-2 specific of breast cancer, SSX-2, NY-ESO-1, or MACE-3 specific of melanoma, described in US patent 6,338,947 ; or antigens specific of renal cancers such as those described in US patent 6,440,663 ; KH-1 and N3 specific of colon cancer, described in US patent 6,238,668.
Immunoaenic and vaccine compositions according to the invention The inventors have found that antibodies directed against a polypeptide derived from the gp41 protein, i.e. the polypeptide of formula (I), are produced during HIV infection of an individual.
More precisely, It has been found, according to the invention a s statistically significant correlation between the expression level of antibodies directed the polypeptide of formula (I), collected from HIV-infected individuals and their level of CD4+ T cells.
It has also been found that these antibodies inhibits the cytotoxicity of NK cells towards CD4+ T cells, in patients infected by HIV.
to Further, the inventors have surprisingly found that antibodies screened for their capacity to inhibit CD4+ T cells NK lysis, react specifically with NKp44L on HIV-1 infected cells (example 5).
More precisely, when cells chronically infected by HIV-1 are pretreated with the antibody described above, their NK-mediated lysis is decreased sharply (Fig. 9E), and treatment of NK cells by an anti-NKp44 mAb produced the same effect (Fig. 9F).
NKp44 is a protein having the amino acid sequence SEQ !D N°2, encoded by a nucleic acid of sequence SEQ ID N°4.
It has also been found that an antibody directed against a 2o polypeptide of formula (I) above, inhibits NKp44L expression onto CD4+T
cells surface, and by the way, decreases sensitivity to NK lysis.
On the opposite, such a result is not obtain with antibodies directed against other polypeptides derived from gp41 protein, for example polypeptides T20 or T21, derived from HR1 or HR2 domains of 2s gp41.
More precisely, it has been found that NKp44L expression was substantially lower in purified CD4+ T cells from two HIV-1 infected patients that were incubated with an antibody directed to the polynucleotide (I), than in purified and then untreated cells or in those 3o treated with a control Ab. (example 6, figure 9) It has also been found that the serum from patients infected by HIV, when depleted in antibodies directed against polypeptide (I) is not able to decrease the CD4+ T cells NK lysis.
These results strongly suggest that the polypeptide of formula (I) s play a key role in inducing NKp44L expression during HIV infection and that the gp41 protein participates in the selective destruction of CD4+ T
cells by activated NK cells.
Without wishing to be bound to any particular theory, the inventors believe that HIV-1 has acquired the ability to use NK cells to disarm the io host immune system by selectively triggering CD4+T cells.
Hence, the blockage of NKp44L expression by antibodies directed against polypeptide (!) could be applied to counteract these deleterious effects.
To illustrate this hypothesis, the inventors have found that there is exists an inverse relationship between NKp44L expression at the CD4+ T
cell surface and the level of antibodies directed against the polypeptide derived from gp41, of formula (I).
Accordingly, another object of the invention is a vaccine composition comprising a polypeptide of formula (I) and an 2o immunoadjuvant compound.
A further object of the invention is an immunogenic composition comprising a polypeptide of formula (I), in combination with at least one physiologically acceptable excipient.
By "immunogenic composition" it is herein intended a substance 2s which is able fio induce an immune response in an individual, and for example to induce the production of antibodies directed against the polypeptide of formula (I).
Preferably, said immunoadjuvant compound is selected in the group consisting of Freund complete adjuvant, Freund incomplete 3o adjuvant, aluminium hydroxide, calcium phosphate, aluminium phosphate, potassium phosphate, Cholera toxin (CT) and its B subunit (CTB), toxins from Bordetella pertusssis (PT), labile toxin (LT) from Escherichia coli, monophosphoryl lipid A, CpG oligonucleotides, imidazoquinolones, oil in water emulsions, comprising squalene and synthetic copolymers, muramyl dipeptides and their derivatives, saponins s and immunostimulating complexes (ISCOMs), and dimethyldioctadecylammonium bromide or chloride (DDA).
For example, to promote a Th2-type immune response, said immunoadjuvant can be selected in the group comprising: aluminium hydroxide, aluminium phosphate, potassium phosphate, calcium io phosphate, or bacteria toxins such as Cholera toxin (CT) and its B
subunit (CTB), toxins from Bordetella pertusssis (PT), or labile toxin (LT) from Escherichia coli. When a Th1-type response is searched, said immunoadjuant can be selected in the group comprising:
monophosphoryl lipid A, CpG oligonucleotides, imidazoquinolones. To is stimulate preferably an antibody response, oil-based adjuvants such as oil in water emulsions, comprising squalene and synthetic copolymers can be used as an immunoadjuvant or also muramyl dipeptides and their derivatives. To promote a mucosal immune response, polysaccharides such as dextran, mannans, glucans, or chitosans can be used as an 2o immunoadjuvant. To enhance antibody production and stimulate T
cytotoxic lymphocytes, saponins and immunostimulating complexes (ISCOMs) can be used as an immunoadjuvant. To induce a humoral and cellular response, a Freund complete adjuvant can be used as an immunoadjuvant. To induce an inflammatory response and a high level of zs antibodies, a Freund uncomplete adjuvant can be used as an immunoadjuvant. To obtain a delayed hypersensitivity lipophilic amines such as dimethyldioctadecylammonium bromide or chloride (DDA) can be used as an immunoadjuvant.
In order to enhance the immunogenicity of the vaccine 3o composition according to the invention, the polypeptide of formula (I), can comprise from 2 to 12 peptides of formula "SWSNKS".
In particular, said antigenic polypeptide, can have the fiollowing formula (III) NH2-PepNt-[(I)"-PepX"]"-PepCt- COOH (III), wherein s - "PepNt" consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the N-terminal end of the polypeptide of formula (III);
- "[(I)"-PepXn]" consists of a polypeptide unit wherein - "(I)~" to - "(I)n" each consists of, one independently from each other, a to polypeptide of fiormula "SWSNKS", with n being an integer from 1 to 12; and - "PepX~" to "PepX"" each consists of, one independently from the other, a spacer polypeptide having an amino acid length varying from 0 to 30 amino acid residues, with n being an integer from 1 to 12;
is - n is the number of [(I)n-PepXn] polypeptide units in said polypeptide, with n being an integer firom 1 to 12; and - "PepCt" consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the C-terminal end of the polypeptide ofi formula (III).
2o Said antigenic polypeptide can be covalently linked through an amino acid residue to a carrier protein or a synthetic polymer.
In order to enhance peptide immunogenicity, the peptide of formula (I) can be covalently linked ("conjugated") to a larger molecule which serves as a carrier.
2s Attachment of the peptide to the carrier can be by one ofi several methods, including linking through a pepfiide Lys using glutaraldehyde (Reichlin, Methods Enzymol. 70: 159-165, 1980) or DCC procedures (for example, Atassi et al., Biochem. Biophys. Acta 670: 300-302, 1981 ), through a Peptide Asp or Glu using DCC (Bauminger et al., Methods 3o Enzymol 70: 151-159, 1980), through a peptide Tyr using bis-diazotized benzidine (Walter et al., Proc. Nat. Acad. Sci. USA 77: 5197-5200, 1980), through photochemical attachment sites (Parker et al., Cold Spring Harbor Symposium - Modern Aoproaches to Vaccines, Ed. Chanock &
Lerner, Cold Spring Harbor Press, New York, 1984), or through a peptide Cys (Liu et al., Biochem. 18: 690-697, 1979).
s Peptide carrier conjugates can be separated from excess free peptide by dialysis or gel filtration. The level of loading of the peptide on the carrier can be determined either using a radioactive tracer to establish the loading level in a particular procedure, or by quantitative amino acid analysis of the conjugate, in comparison with the unloaded to carrier. It is convenient, when using the latter technique, to incorporate a unique non-natural amino acid into the peptide, at the N-terminal or C-terminal side, such as Nle, which can then serve as a quantitative marker for peptide incorporation, as measured by amino acid analysis of the conjugate. This Nle can also function as a spacer between the antigenic is site and any amino acid incorporated to facilitate attachment, such as Cys, Lys, or Tyr, as described above.
Preferably, said carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin, or diphtheria toxoid.
2o In a vaccine composition according to the invention, said synthetic polymer can be a multiple branch peptide construction comprising a core matrix comprised of lysine residues.
Radially branched systems using lysine skeletons in polymers have been used by J. P. Tam [Proc. Natl. Acad. Sci. U.S.A., 85, 5409 2s 5413 (1988)] to develop antigens without the use of carriers. Those antigens were designed to generate vaccines against a variety of diseases. Specifically, antigens for generating vaccines against HIV
infection are described by Tam in PCT pafient application ser. no.
W093/03766, and in US patent Application US5,229,490.
3o The core matrix is preferably a dendritic polymer which is branched in nature, preferably with each of the branches thereof being identical. The core matrix is based on a core molecule which has at least two functional groups to which molecular branches having terminal functional groups are covalently bonded. Exemplary for use to form the core matrix is lysine. A central lysine residue is bonded to two lysine s residues, each through its carboxyl group, to one of the amino groups of the central lysine residue. This provides a molecule with four amino groups, which may be a core matrix for a structure comprising four polypeptides of formula (I). The manufacture of the above structures, has been know in the art. See, e.g., Tam et al., J. Immun. 148, 914-920 io (1992) and Wang et al., Science, 254, 285-288 (1991 ).
Additionally, spacers between said polypeptide and said carrier protein or synthetic polymer can be added. A peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds is into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1 ) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure 2o that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Qther near neutral amino acids, such as Thr and Ala may also be used in the linker 2s sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985;
Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Pat.
No. 4,935,233 and U.S. Pat. No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences 3o are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.
The invention concerns also a vaccine composition comprising a polypeptide comprising the amino acid sequence SWSNKS, said s polypeptide, being covalently linked through an amino acid residue to a carrier protein or to a synthetic polymer.
Preferably, said carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin, or diphtheria toxoid.
io The synthetic polymer can be a multiple branch peptide construction comprising a core matrix comprised of lysine residues.
Spacers between said polypeptide and said carrier protein or synthetic polymer can be introduced.
Prefrably, In the vaccine composition cited immediately above, is there are spacers between said polypeptide and said carrier protein or synthetic polymer.
This invention is also directed to the use of an antibody directed against a polypeptide of formula (I) for manufacturing a pharmaceutical composition for treating a disease linked to the infection of an individual 2o with a virus of the HIV family.
Additional compounds In a preferred embodiment, the vaccine composition according to the invention, further comprises one or more components selected from as the group consisting of surfactants, absorption promoters, water absorbing polymers, substances which inhibit enzymatic degradation, alcohol, organic solvents, oils, pH controlling agents, preservatives, osmotic pressure controlling agents, propellants, water and mixture thereof.
3o Examples of appropriate supplementary carriers include, but are not limited to, sterile water, saline, buffers, phosphate-buffered saline, buffered sodium chloride, vegetable oils, Minimum Essential Medium (MEM), MEM with HEPES buffer, etc.
Optionally, the vaccine composition of the invention may contain conventional, secondary adjuvants in varying amounts depending on the s adjuvant and the desired result. The customary amount ranges from about 0.02% to about 20% by weight, depending upon the other ingredients and desired effect.
Examples of suitable secondary adjuvants include, but are not limited to, stabilizers; emulsifiers; aluminum hydroxide; aluminum io phosphate; pH adjusters such as sodium hydroxide, hydrochloric acid, etc.; surfactants such as Tween® 80 (polysorbate 80, commercially available from Sigma Chemical Co., St. Louis, Mo.); liposomes; iscom adjuvant; synthetic glycopeptides such as muramyl dipeptides; extenders such as dextran or dextran combinations, for example, with aluminum is phosphate; carboxypolymethylene; bacterial cell walls such as mycobacterial cell wall extract; their derivatives such as Corynebacterium parvum; Propionibacterium acne; Mycobacterium bovis, for example, Bovine Calmette Guerin (BCG); vaccinia or animal poxvirus proteins;
subviral particle adjuvants such as orbivirus; cholera toxin; N,N-2o dioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine (avridine);
monophosphoryl lipid A; dimethyldioctadecylammonium bromide (DDA, commercially available from Kodak, Rochester, N.Y.); synthetics and mixtures thereof. Desirably, aluminum hydroxide is admixed with other secondary adjuvants or an immunoadjuvant such as Quil A.
as Examples of suitable stabilizers include, but are not limited to, sucrose, gelatin, peptone, digested protein extracts such as N~-Amine or NZ-Amine AS. Examples of emulsifiers include, but are not limited to, mineral oil, vegetable oil, peanut oil and other standard, metabolizable, non-toxic oils useful for injectables or intranasal vaccines compositions.
3o These adjuvants are identified herein as "secondary" merely to contrast with the above-described immunoadjuvant compounds.
Conventional preservatives can be added to the vaccine composition in effective amounts ranging from about 0.0001 % to about 0.1 % by weight. Depending on the preservative employed in the formulation, amounts below or above this range may be useful. Typical s preservatives include, for example, potassium sorbate, sodium metabisulfite, phenol, methyl paraben, propyl paraben, thimerosal, etc.
The choice of inactivated, modified or other type of vaccine composition and method of preparation of the improved vaccine composition formulation of the present invention are known or readily io determined by those of ordinary skill in the art.
When the polypeptide (I) is not covalently bound to an immunoadjuvant, in the vaccine composition acording to the invention, a pharmacologically effective amounfi of the immunoadjuvant compound described above may be given, for example orally, parenteraNy or is otherwise, concurrently with, sequentially to or shortly after the administration of the polypeptide of formula (I).
As a general rule, the vaccine composition of the present invention is conveniently administered orally, parenterally (subcutaneously, intramuscularly, intravenously, intradermally or intraperitoneally), 2o intrabuccally, intranasally, or transdermally.
In vitro screeninpr and diagnosis methods according to the invention a) screening methods 2s The inventors have surprisingly found that a specific polypeptide, derived from the gp41 protein of HIV, markedly enhances the expression of the Nkp44L protein on CD4+ T-cells surface.
The invention also concerns a first method for the in vitro screening of compounds for preventing or treating a disease linked with 3o the infection of an individual with an HIV virus, comprising the steps of (i) incubating a candidate compound to be tested with a polypeptide of formula (I), (ii) assaying for the binding of the candidate compound to be tested with a polypeptide of formula (I).
s The binding of the candidate compound to the polypeptide of formula (I) can be carried on by the one skilled in the art, for example by using a Two-hybrid system. Other means, known from the one skilled in the art can be used for the binding assays such as the use of bio sensor techniques (Edwards and Leatherbarrow (1997) or also by Szabo et al.
to (1995)), affinity chromatography, or High Throughput Screening (HTS), (Leblanc et al 2002).
The candidate compounds, which may be screened according to the screening method above, may be of any kind, including, without being limited to, natural or synthetic compounds or molecules of is biological origin such as polypeptides.
Preferably, step (ii) consists of subjecting to a gel migration assay the mixture obtained at the end of step (i) and detecting the complexes formed between the candidate compound and the polypeptide of formula 2o The gel migration assay can be carried out as known by the one skilled in the art.
The detection of the complexes formed between the complexes formed between the candidate compound and the polypeptide according to the invention can be easily observed by determining the stain position 2s (protein bands) corresponding to the proteins analysed since the apparent molecular weight of a protein changes if it is part of a complex with another protein.
On one hand, the stains (protein bands) corresponding to the proteins submitted to the gel migration assay can be detected by specific 3o antibodies for example antibodies specifically directed against a polypeptide of formula (I). One the other hand, a polypeptide of formula (I) can be tagged for an easier detection of the proteinicandidate compound on the gel. For example, the polypeptide according to the invention can be fused to GST, HA, a poly-Histidine chain, or other detectable molecules in order to facilitate the identification of the different s proteins on the gel.
The invention further concerns a second method for the in vitro screening of compounds for preventing or treating a disease linked to the infection of an individual with an HIV virus, comprising the steps of:
a) (i) bringing into contact a first CD4+ T-cell culture with a candidate io compound, and HIV virus ;
(ii) bringing into contact a second CD4+ T-cell culture with HIV virus, in the absence of said candidate compound ; and b) detecting the presence of NKp44L at the CD4+ T-cells surface issued from the culture (i) and (ii).
is The detection of the presence of NKp44L at the CD4+ T-cells surface can be carried out as known by the one skilled in the art, for instance by a cytofluorometric analysis as it is described in the part Material and methods, corresponding to the example 6.
Preferably, the method described above, comprises an additional 2o step (c) which consists of selecting positively the candidate compound as a therapeutical agent when the level of expression of NKp44L at the CD4+ T-cells surface issued from the culture (ii) is higher than the level of expression of NKp44L at the CD4+ T-cells surface issued from the culture (i).
2s The comparison of the level of expression of NKp44L at the CD4+ T-cells surface can be assessed by counting the number of CD4+
T cells expressing NKp44L on their surface, using a fluorescence activated cell sorter (FACS), as described in the corresponding Material and Methods section.
3o Alternatively, the detection of the presence of NKp44L at the CD4+ T-cells surface can be carried out indirectly, by measuring the NK
lysis activity of CD4+ T cells, as it is described in the section Material and Methods.
This particular embodiment of the step (b) of the screening method above, despite it consists of an in vitro method, has the technical s advantage to directly reflect the therapeutical potential of the candidate compound by directly evidencing the biological activity of said candidate compound, as regards preventing the CD4+ T-cells cytolysis by the activated NK cells.
The activated NK cells may consist of cells from a NK cell line, to such as the NK92 cell line described by Gong et al. (1994) or may consist of a primary culture of normal human purified NK cells.
The CD4+ T-cells that express the NKp44L protein may consist of CD4+ T-cells, eventually under the form of a cell line, that have been transfected with a vector that allow the expression by said cells of the is NKp44L protein, or may consist of CD4+ T-cells that were initially purified from a blood sample of an HIV-infected patient.
In a specific embodiment of the screening method above, the activated NK cells and the CD4+ T-cells are autologous in that they both come from the same HIV-infected patient.
2o Preferably, the cytolysis measure consists of the conventional technique wherein the CD4+ T-cells, which are the target cells, are initially rendered radioactive with 5~Cr, and wherein the cytolysis value consists of the percentage of cell lysis, as measured by the amount of 5~Cr that is released in the cell culture medium by the lysed CD4+ T-cells.
2s Most preferably, the cytolysis value is obtained by assaying the cytolytic activity of the NK cells at increasing effector (NK cells) to target (CD4~ T-cells) ratios, for example from 1:1 to 50:1 effector : target cell ratios.
Candidate compounds for use in the screening methods described 3o immediately above can be selected among the candidate compounds which binds to one or several polypeptides of formula (I).
Accordingly, the invention also concerns a method for the in vifro screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV virus, comprising the steps of (i) submitting a candidate compound to the first screening method s above, and (ii) submitting a candidate compound positively selectionned at step (i) to the second screening method described immediately above.
b Diagnosis methods of the invention ro The inventors have found that, that antibodies directed against polypeptide (I) are produced during HIV infection.
it has also been found according to the invention a statistically significant correlation between the expression level of antibodies directed against polypeptide (I) collected from HIV-infected individuals and the is level of CD4+ T cells.
it has been found according to the invention that the level of these antibodies decrease during the progression of HIV infection, especially as regards the development of the patient's immunodeficiency caused by the progressive depletion of his CD4+ T cells.
ao Besides, the inventors have found that this kind of kinetics is specific for antibodies directed against polypeptide of formula (I) and is not observed with antibodies directed against peptides T20 or T21 derived from HR1 and HR2 domains of gp41.
It flows from the experimental results obtained by the inventors as which are briefly described above that the level of antibodies directed against a polypeptide (I), contained in the serum of an individual, reveals itself to consist of an accurate biological marker of the progression status of the infection of an individual with an HIV virus. Further, the expression level said antibodies consists of a novel biological marker of the state of 3o advancement of the HIV infection endowed with a very high biological significance, since it has been shown by the inventors that the level of antibodies directed against polypeptide (I) is more important at the beginning of infection of a patient by HIV.
Accordingly, the invention also concerns a method for the in vitro assessment of the progression status of the infection of an individual with s an HIV virus, wherein said method comprises the step of detecting in a sample from said individual, antibodies directed against a polypeptide of formula (I).
As used herein an "HIV" virus consists of either an HIV-1 or an HIV-2 virus, and more particularly any virus strain or isolate of an HIV-1 or an to HIV-2 virus.
As used herein, the "assessment of the progression status" of the infection consists of raw experimental data indicative of the immunological status of the HIV-infected patient tested; Hence, as already mentioned above, there is a statistically relevant correlation is between the amount of antibodies directed against the polypeptide of formula (I) and the CD4+ T cells count.
The sole detection of antibodies directed against a polypeptide of formula (1) might nofi be sufficient for a global accurate clinical diagnosis, or prognosis, of the progression status of the disease within the patient 2o tested. Thus, the detection of antibodies directed against a polypeptide of formula (I) might be completed by, or combined with, other diagnosis or prognosis markers of the disease, for example one of the prior art markers that have previously been cited in the present specification.
The detection of antibodies directed against a polypeptide of 2s formula (I) can be achieved using known techniques such as ELISA or RIA tests.
Methods of treatment according to the invention This invention also deals with a method for preventing or for 3o treating a disease linked to the infection of an individual with a virus of the HIV family, wherein said method comprises a step of administering to a patient in need of such treatment an effective amount of an immunogenic or a vaccine composition comprising a polypeptide of formula (i) in combination with an immunoadjuvant coompound.
In a specific embodiment of the invention, said method comprises s the following steps - preparing a purified batch (HPLC, > 95%) of polypeptide comprising the aminoacid sequence (II), linked to diphteria toxoid, - Injecting diphteria toxoid alone to a first "control" group of mammals to - Injecting the polypeptide comprising the aminoacid sequence (II), linked to diphteria toxoid, to a second "test" group of mammal, Preferably, when the mammals used are of the Macaca mulatta species, they received 0,5 mg per mammal, and per injection of diphteria toxoid, linked or not, to the polypeptide cited above, followed by 3 new is injections 3, 6 or 9 weeks later, in combination with Freund's incomplete adjuvant, - infecting the two groups of mammals with SHIV33, two weeks after the last injection, with 1 ml of a dilution at 50 TCID50/ml.
-Collecting samples consisting of serum and PBMC (peripheral 20. blood mononuclear cells) at day 0, and 1 week after each injection (before infection) and then every week after infection by SHIV, -analysing the collected samples.
These analyses can comprises, without limitation, the control of the general aspect of the sample, the measurement of the amount of CD4+ T
2s cells using a FACS, the measurement of the viral load by RT-PCR, the determination of the seroconversion by detecting antibodies directed against Env protein by EIA technique, the detection of antibodies directed against polypeptide of formula (II) by ELISA.
These analyses can comprise also the study of the effects of 3o antibodies produced by said mammals on cells infected by HIV, and for example chronically infected cells. These cells are for example, U2 cells infected by HIV-sf2, Jurkat cells infected by H1V-BRU, or CD4+ T cells infected by BRU or collected from HIV infected patients.
Further, these analyses can comprise the measurement of NKp44L expression level, by FRCS, the analysis of P24 amount, by EIA, s or the analysis of NK cytotoxic activity of several strains of NK cells, such as autologous or allogenic NK92, NK3.3, or NKL cells, using a 5~Cr test as described below.
A further object of the invention consists of a method for preventing or for treating a disease linked to the infection of an individual io with a virus of the HIV family, wherein said method comprises a step of administering to a patient in need of such treatment an effective amount of an antibody directed against the polypeptide of formula (I) The invention concerns also the use of a ligand compound which specifically binds to the polypeptide of formula (I), for manufacturing a is pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family.
The invention also deals with the use of a polypeptide of formula (I), for manufacturing a vaccine composition for treating a disease linked to the infection of an individual with a virus of the HIV family.
2o The present invention is further illustrated by, without in any way being limited fio, the following examples.
EXAMPLES
A. General material and methods 2s A.1 HIV-1 infected donors.
Blood samples of 25 HIV-1-infected patients were obtained from consenting donors at Hopital Pitie-Salpetriere. Bio-clinical examinations included routine determinations of the viral load, total blood and CD4~ T
lymphocyte counts.
3o As control group, Blood samples from 20 uninfected donors were obtained by leukapheresis from the blood bank (Hopital Pitie-Salpetriere).
A.2 Cytofluorometric analysis A three-colors FACS analysis was performed on freshly harvested PBMC. Isotype-matched immunoglobulin served as the negative control s (BD). Cells were incubated 1 h at 4°C, with the appropriate cocktail of antibodies. Anti-CD3; anti-CD4; anti-CD3, anti-CD56, anti-NKp44, anti-NKp46 or anti-NKp44L mAb. Erythrocytes were lysed using the FACS
lysing solution (BD). A minimum of 20,000 leucocytes was analyzed on a FACScan, as previously described.
to To measure the expression of cell surface activation markers, PBMC were stained with PE- or FITC-conjugated anti-HLA-DR, anti-CD69, anti-CD25, or anti-CD71 (all from BD) and analyzed by FACS.
A.3 Purification of T CD4~ cells expressing NKp44L
is CD4~ T cell subset sorting was performed using the RosetteSepCD4+ enrichment kit (StemCell). CD4+ T expressing NKp44L
were positively selected by a two step magnetic separation, CD4+ T cells were incubated with 10 pglml of anti-NKp44L for 1-h at RT, followed by treatment with goat anti IgM mouse-coated Dynabeads (Dynal) at a 2o bead-to-cell ratio of 10:1 for 30 min at RT. The cell fraction purity was determined by FACS analysis.
A.4 Isolation of primary NK cells and NK cytotoxicity assays NK lines were generated from PBMC, and then purified using the 2s StemSep cell separation system and the NK cell enrichment antibody cocktail (StemCell technologies). NK purified cells were cultured in MyeloCult H5100 medium (StemCell technologies) supplemented with 100 units rhlL-2 (Boheringer). The purity of these preparations was evaluated by flow cytometry after staining with anti-CD3 (BD), anti-CD56 30 (BD), anti-NKp44, and anti-NKp46 mAbs.
The cytolytic activity was assayed in 4-h 5~Cr-release assay as previously described. Briefly, the target cells were labeled for 2-h at 37°C
with 100 pCi per 106 cells Na5~Cr (Amersham), and washed twice with culture medium. The target cells were then distributed in round-bottomed s 96-well microtiter plates (4 x 103 cells per well), and the effector cells were added at several E/T rario. The plates were incubated 4-h at 37°C.
The supernatant were then collected and S~Cr-release was measured in a gamma counted. In experiments in which Abs were included, these were added to final concentration of 20 pg/ml. The relative specific 5'Cr-to release was calculated according to conventional methods. Values for spontaneous 5~Cr-release, which are deducted in the calculation, were between 10 and 20% of the total incorporated radioactivity. The results are presented after subtraction of the nonspecific lysis obtained with control targets. Each point represents the average of triplicate values.
is The range of the triplicates was always within 5% of their mean.
A.5 Statistical analysis Correlation analyses were performed using Sperman's non-parametric rank correlation analysis. All calculations were performed 2o using the GraphPad Prism.
B. Material and Methods of the examples -6 B.1 Purification of T CD4+ cells 2s CD4+ T cell subset sorting was performed using the RosetteSepCD4+ enrichment kit (StemCell). The cell fraction purity was determined by FACS analysis.
B.2 Cytofluorometric analysis 3o A two-colors FRCS analysis was performed on purified CD4+ T
cells. Isotype-matched immunoglobulin served as the negative control (BD). Cells were incubated 1 h at 4°C, with the appropriate cocktail of antibodies. anti-CD4 or anti-NKp44L mAb. A minimum of 20,000 CD4+ T
cells was analyzed on a FACScan, as previously described. The intra-cellular expression of NKp44L was realized as previously described, s briefly, the cells were incubated in 4% PFA buffer for 20 min, then washed in stained in presence of 0.1 % saponin/PBS/1 % BSA buffer at 4°C. the cells were then analyzed by FACS.
B.3 Isolation of primary NK cells and NK cytotoxicity assays.
to NK lines were generated from PBMC, and then purified using the StemSep cell separation system and the NK cell enrichment antibody cocktail (StemCell technologies). NK purified cells were cultured in MyeloCult H5100 medium (StemCell technologies) supplemented wifih 100 units rhlL-2 (Boheringer). The purity of these preparations was 1s evaluated by flow cytometry after staining with anti-CD3 (BD), anti-CD56 (BD), anti-NKp44, and anti-NKp46 mAbs.
The cytololytic activity was assayed in 4-h 5'Cr-release assay as previously described. Briefly, the target cells were labeled for 2-h at 37°C
with 100 pCi per 106 cells Na5'Cr (Amersham), and washed twice with 2o culture medium. The target cells were then distributed in round-bottomed 96-well microtiter plates (4 x 103 cells per well), and the effector cells were added at several E/T rario. The plates were incubated 4-h at 37°C.
The supernatant were then collected and 5'Cr-release was measured in a gamma counted. In experiments in which Abs were included, these 2s were added to final concentration of 20 pg/ml. The relative specific 5'Cr-release was calculated as previously described. Values for spontaneous 5'Cr-release, which are deducted in the calculation, were between 10 and 20% of the total incorporated radioactivity. The results are presented after subtraction of the nonspecific lysis obtained with control targets.
3o Each point represents the average of triplicate values. The range of the triplicates was always within 5% of their mean.
B.4 Recombinant vaccinia virus expression HIV-1 protein.
Purified CD4+ T cells were infected with wild type vaccinia virus (WT) or with the various recombinant vaccinia virus at a multiplicity s infection of 20 PFU/cell were used as target cells. Recombinant vaccinia viruses for HIV-1-LAI Gag, Pol, Env, Nef, Tat and Vif proteins were provided by Transgene (Strasbourg, France).
B.5 Peptides and pools of peptides.
to The synthetic 15-mers peptides were purchased from Epytop (Nimes, France) or kindly provided by Agence Nationale de la Recherche sur le SIDA. All were more than 80% pure as shown by HPLC profiles.
Pools of peptides included around 10 different peptides and each peptide overlap the previous continuous peptide for 11 residues.
is B6. mAbs screened for their capacity to inhibit NK Iysis 11. Anti-NKp44 (44/8; IgG1) and anti-NKp44L mAb (#7.1; IgM) were obtained from 5-weekold BaIB/c mice immunized with the CIonaCell-HY
2o hybridoma cloning kit, according to the manufacturer's instructions (StemCell Technologies Inc.). The anti-mouse-peroxidase hybridoma screening reagent (Roche) and ELISA were used to select antibodies.
Anti-NKp44 (44/8) mAb was prepared by immunizing the mice with NKp44-Ig protein, after specific deletion of the IgG1 human Fc fragment.
2s To obtain #7.1 mAb (IgM), mice were immunized with acid-treated U2-sf2 cells. These cells were prepared as previously described (S. Sumitran-Karuppan , E. Moller, Transpl. Immunol. 4, 163, 1996.). Briefly, one million U2-Sf2 cells were washed 3 times in PBS and treated for 5 min on ice in an acid buffer prepared by mixing equal volumes of 0.263 M citric 3o acid and 0.123 M Na2HP04 containing 1 % (w/v) BSA. After three more washes, the cells were resuspended in PBS and then irradiated and injected into the mice. All hybridomas were analyzed with 51 Cr cytotoxic assays with untreated or acid-treated 721.221 cells as targets, and the specificity of the anti-NKp44 hybridoma was analyzed by ELISA with different fusion proteins. The #7.1 mAb (IgM) mAb was purified on a s mannan-binding protein (MBP) column (Pierce), after ammonium sulfate precipitation (50% saturated solution); the anti-NKp44 mAb was purified on a protein A/G column (Pierce). The purity of each purified mAb was confirmed on SDS -PAGE.
o C. RESULTS
Example 1 Effects of several HIV viral proteins on NKp44L
expression The effect of HIV viral protein on NKp44L expression was is examined using infection with recombinant vaccinia virus expressing HIV
viral protein. As shown in Figure 1, the expression of NKp44L was markedly enhanced in CD4+ T cells infected with vaccinia virus expressing the gp160 (33,9%) or the gp41 HIV Env proteins (35,6%). In contrast, neither other HIV proteins tested, like Gag, Pol, Tat, nef, vif, or 2o gp120, influenced the cell surface expression of NKp44L protein.
Furthermore, the role of the Env protein to enhance the expression of NKp44L was confirmed in a non-viral system. Purified CD4+ T cells were treated with recombinant gp160 protein provided of two different origins, and as shown in Figure 2A, these gp160 recombinant proteins influenced 2s the expression of NKp44L. Indeed, 10,7% and 9,6% of CD4+ T cells expressed NKp44L after treatment with the gp160-A and gp160-B, respectively. On the other hand, no effect was observed with untreated cells or cells incubated with a control protein. All together, these results show that the recombinant gp160 protein markedly enhances the cell 3o surface expression of NKp44L on CD4+ T-cells surface.
Example 2 aa160 induces the NK Iysis of CD4+ T cells.
Comparison of NK lysis activity from the untreated cells, the cells treated with the control protein or the cells treated with the both s recombinant gp160 proteins (Figure 2B), shows that target cell lysis was increased in the presence of CD4+ T cells cultured with recombinant gp160 protein. The use of two different types of recombinant gp160 proteins indicates that the procedure used to induce over-expression of NKp44L and increased of NK lysis activity had no influence on the io outcome of the experiments. Together, these results indicate that gp41 HIV Env protein was required for the over-expression of NKp44L
correlated with a strong increased of NK lysis activity.
Example 3 identification of the peptide motif of the ap41 Env protein is involved in the increased of NK Iysis activity, The effect of pool of overlap peptides prepared, as described in the Materials & Methods section, has been tested, to include all of the gp41 protein. CD4+ T cells were incubated with 5 pg of each pool of peptides 2o and tested against activated NK cells. As shown in Figure 3, NK lysis was increased in cells incubated with the pool of peptides named gp41 C, but not with all of the other pool of peptides. The expression of NKp44L
in purified CD4+ T cells treated with each of the pool of peptides has been tested. This receptor was only detectable in cells treated with pool 2s gp41 C, and the percentage of positive cells was 13,3%. In no instance, NKp44L was detected on the cells incubated with the other pool of peptides tested. This suggested that one or several peptide motifs included in the pool gp41 C was directly implicated in the increased of NK
lysis via the over-expression of NKp44L. Repeated experiments with all 30 of the peptides included in the pool gp41 C was then tested. As shown in Figure 4A, the NK cytotoxic activity was strongly increased in presence of the peptides gp41-C145, gp41-C146, and gp41-C147. By contrast, with the other peptides tested, the NK lysis activity remained low, closed to the background. In parallel, the expression of NKp44L was increased after pretreatment of CD4+ T cells with the peptides gp41-C145, gp41-s C146, and gp41-C147, with a percentage of positive cells varied between 22 and 16%, but not with the other peptides (less than 7% of positive cells) (Figure 4B). These results indicated that a peptide specific to gp41 Env HIV protein could increased a NK lysis activity. Additional support to this conclusion come from that the continuous peptides named gp41-io C145, gp41-C146, and gp41-C147 included a common peptide motif NH2-SWSNKS-COOH, This motif specific to the gp41 HIV-1 protein was strongly conserved. After having shown that some continuous peptides of the gp41 are some major mediators of NK lysis, it was important to assess if the peptide motif NH2-SWSNKS-COOH was directly implicated is in the NK lysis of CD4+ T cells. Preliminary experiment with this 6-mers peptide shown any increased of cell surface expression of NKp44L or NK
cytotoxic activity, suggesting that this sequence is too small or too rapidly attack by some peptidases. However, to test this hypothesis, two 15-mers peptides derived from gp41-0146 (WT) included some mutation 2o inside the NH2-SWSNKS-COOH motif (Ctl1 ) or in all of the 15-mers sequence (Ctl2) have been constructed (figure 5A). As shown in Figure 5B, the NK cytotoxic activity was strongly increased in presence of the peptide WT. By contrast, with untreated cells (none) or the treated with the both control peptides. Similar pattern was observed concerning the 2s cell surface expression of NKp44L, indeed, in cells treated with the WT
peptide, approximately 17,4% of CD4 T cells expressed this marker. By contrast, the percentage of NKp44L+ cells was less than 4% in untreated cells or cells treated by the control peptides. These results show that the NH2-SWSNKS-COOH motif included in the gp41 protein is strongly 3o implicated in the NK lysis of CD4+ T cells.
The effect of gp41 peptide is time dependant (Figure 6). NK lysis activity started after 30 min of incubation with the WT peptide and approached a maximum closed to 4-days. On the other hand, no significant effect is observed after treatment with the untreated cells or the cells treated with s the control peptides. Furthermore, the increased of NK lysis activity is strongly inhibited after pretreatment of cells with anti-NKp44L mAb, confirming that the NK activity is directly correlated with an increase of cell surface expression of NKp44L, in cells treated with the WT peptide (Figure 6C). However, kinetic study of the cell surface expression of to NKp44L revealed that this receptor was rapidly expressed at the cell surface, indeed after 10 min of treatment with WT peptide, around 10%
of CD4+ T cells expressed this protein, and the maximun of expression (approximately 30%) was obtained 4-days after treatment. The very fast cell surface expression of NKp44L suggested an absence of new is synthesis of NKp44L, and suggested that this protein was present inside the CD4+ T cells cultured with IL2. This hypothesis was confirmed by an intracellular staining of NKp44L. As show in Figure 6D, high expression of NKp44L was detectable inside the cells, and this independently of the presence of peptides.
Example 4 Cell surface expression of NKp44L of different human cells As shown on figure 7, the surface expression of NKp44L on K562, Jurkat, and resting PBMC has been tested. The cells were incubated 2s with 1 pg/ml of anti-NKp44L mAb anti-NKp44L mAb (grey thick line) or with the IgM isotype control (black thin), and analyzed by flow cytometry.
It is clearly shown that, contrary to PBMC, tumor cells, like jurkat, and K562 cells express NKp44L on their surface.
Exemple 5 Identification of #7.1, an anti-NKp44L mAb that specifically inhibits NKp44- mediated NK Iysis.
To study the related function and expression of this ligand during HIV-1 s infection, a library of mAbs screened for their capacity to inhibit NK lysis has been tested. One of them, the #7.1 mAb, revealed an epitope expressed on NKp44L. Specific staining with this mAb was found in HIV-infected U2 cells only, not in uninfected U2 cells (Fig.BB), and it yielded a level of staining similar to that of the NKp44-Ig fusion protein (compare to Fig. 8A and 8B). Inhibition of the #7.1 mAb staining by this fusion protein confirmed that #7.1 mAb specificaly interact with a NKp44 ligand (NKp44L) (Fig. 8C). A control experiment showed no effect with the NKp46-Ig fusion protein (Fig. 8C). Furthermore, when U2 cells chronically infected by the HIV-1 Sf2 strain were pretreated with the #7.1 is mAb, their NK-mediated lysis decreased sharply (as much as 40%) (Fig.BD). Treatment of NK cells by the anti-NKp44 mAb produced the same effect (Fig. SE).Note that in both series of experiments the magnitude of the lysis obtained in the presence of anti-NKp44 or 7.1 mAb was similar to that observed with uninfected cells. We obtained similar 2o results with Jurkat cells chronically infected by the HIV-1 BRU strain (data not shown). Together, these data strongly suggest that NKp44L is expressed during HIV-1 infection and that #7.1 mAb reacts specifically with NKp44L on HIV-1 infected cells.
2s Exemple 6 Critical role of the NH2-SWSNKS-COOH motif from the ~p41 HIV protein A rabbit anti-gp41-C146 peptide polyclonal Ab has been tested for its capacity of inhibition of NKp44L expression and for sensitivity to NK lysis.
Briefly, highly purified peptide (gp41-C146 peptide) (>95%) was linked to 3o the KLH and injected in several rabbits. Serum titres were determined by ELISA on PeptiPtaks. Antibodies were purified by chromatography.
NKp44L expression was substantially lower (7.8%) in purified CD4+ T
cells from two HIV-1 infected patients that were incubated with purified anti-gp41-C146 polyclonal Ab than in purified and then untreated cells s (27.2%) or in those treated with a control Ab (27.9%) (Fig. 9E). This effect v~ras confirmed by the drastic inhibition of NK activity in the presence of the anti-gp41-C146 polyclonal Ab(Fig.9F). These results strongly suggest that the gp41 NH2-SWSNKS-COOH motif plays a key role in inducing NKp44L expression during HIV infection and that the io gp41 protein participates in the selective destruction of CD4+ T cells by activated NK cells.
REFERENCES
Arneisen JC, Capron A. Cell dysfunction and depletion in AI DS: the programmed cell death hypothesis. Immunol Today 1991;12(4):102-5.
Bagnarelli P, Menzo S, Valenza A, Manzin A, et al. Molecular profile s of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol 1992;66(12):7328-35.
Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni R., 1999, NKp44, a triggering receptor involved in tumor cell lysis by activated human to natural killer cells, is a novel member of the immunoglobulin superfamily, J Exp Med 1999 Mar 1;189(5):787-96 CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19.
is . CDC. Revision of the surveillance case definition of acquired imrnunodeficiency syndrome. MMWR 1987;36:3S-15S.
Clark SJ, Saag MS, Decker WD, Campbell-Hill S, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324(14):954-60.
20 . Coombs RW, Collier AC, Allain JP, Nikora B, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321 (24):1626-31.
Edwards and Leatherbarrow, 1997, Analytical Biochemistry, 246 : 1-6.
Ernbretson J, Zapancic M, Ribas JL, Burke A, et al. Massive covert 2s infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362(6418):359-62.
Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993a;262(3136):1011-8.
. Felici F., 1991, J Mol Biol, 222 : 301-310.
Finkel TH, Tudor-Williams G, Banda NK, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature Medicine s 1995;1 (2):129-34.
Fox CH, Kotler D, Tierney A, Wilson CS, Fauci AS. Detection of HIV-1 RNA in the lamina propria of patients with AIDS and gastrointestinal disease. J Infect Dis 1989;159(3):467-71.
Garry RF. Potential mechanisms for the cytopathic properties of HIV.
1o AI DS 1989;3(11 ):683-94.
Golding H, Shearer GM, Hillman K, Lucas P, et al. Common epitope in human immunodeficiency virus I (HIV) I-GP41 and HLA class II
elicits immunosuppressive antibodies capable of contributing to immune dysfunction in HIV-infected individuals. J Clin Invest is 1989;83(4):1430-5.
Gong et al., 1994, Leukemia, vol.8 (4):652-658.
Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321 (24):1621-5.
20 . Ho DD, Neumann AU, Perelson AS, Chen W, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
Hoxie JA, Alpers JD, Rackowski JL, Huebner K, et al. Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV.
2s Science 1986;234(4780):1123-7.
Hugin AW, Vacchio MS, Morse HC III. A virus-encoded superantigen in a retrovirus-induced immunodeficiency syndrome of mice. Science 1991;252(5004):424-7.
. Janeway C. Immune recognition. Mls: makes little sense. Nature 1991;349(6309}:459-61.
Koenig S, Earl P, Powell D, Pantaleo G, et al. Group-specific, major histocompatibility complex class-I restricted cytotoxic responses to s human immunodeficiency virus I (HIV-1 ) envelope proteins by cloned peripheral blood T cells from an HIV-1 infected individual. Proc Natl Acad Sci USA 1988;85(22):8638-42.
Koga Y, Lindstrom E, Fenyo EM, Wigzell H, Mak TW. High levels of heterodisperse RNAs accumulate in T cells infected with human io immunodeficiency virus and in normal thymocytes. Proc Natl Acad Sci USA 1988;85(12):4521-5.
Kohler G. and Milstein C., 1975, Nature, 256 : 495.
Kozbor et al., 1983, Hybridoma, 2(1 ) : 7-16.
Laurent-Crawford AG, Krust B, Muller S, Riviere Y, et al. The is cytopathic effect of HIV is associated with apoptosis. Virology 1991;185(2):829-39.
Leblanc V, Delaunay V, Claude Lelong J, Gas F, Mathis G, Grassi J, May E. 2002 . Anal Biochem. 2002 Sep 15; 308(2):247-54.) 20 . Leger OJ et al., 1997, Hum Antibodies , 8(1 ) : 3-16.
Leonard R, ~agury D, Desportes I, Bernard J, et al. Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection. Proc Natl Acad Sci USA 1988;85(10):3570-4.
Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG. AIDS
2s retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science 1986;232(4754):1123-7.
Lucas A.H., 1994, In : Development and Clinical Uses of Haemophilus b Conjugate.
Lyerly HK, Matthews TJ, Langlois AJ, Bolognesi DP, Weinhold KJ.
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci USA
s 1987;84(13):4601-5.
Martineau P., Jones P., Winter G., 1998, J Mol Biol, 280(1 ) : 117-127.
Michael NL, Vahey M, Burke DS, Redfield RR. Viral DNA and mRNA
correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV
io disease. J Virol 1992;66(1 ):310-6.
Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995;154(10):5555-66.
is . Oldenburg K.R. et al., 1992, Proc. Natl. Acad. Sci. USA, 85(8) : 2444-2448.
Pantaleo G, Fauci AS. Apoptosis in HIV infection. Nature Medicine 1995b;1 (2):118-20.
Pantaleo G, Graziosi C, Demarest JF, Butini L, et al. HIV infection is 2o active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993b;362(6418):355-8.
Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993a;328(5):327-35.
2s . Parmley and Smith, 1988, Gene, 73 : 305-318.
Pauza CD, Galindo JE, Richman DD. Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodefiiciency virus type 1 infection of CEM cells. J Exp M ed 1990;172 (4):1035-42.
. Piatak M Jr, Saag MS, Yang LC, Clark SJ, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive s PCR. Science 1993;259(5102):1749-54.
Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224(4648):497-500.
Reinmann KA et al.., 1997, AIDS Res Hum Retroviruses, 13(11 ) : 933-l0 943.
. Ridder R., Scmitz R., Legay F., Gram H., 1995, Biotechnology (N Y), 13(3) : 255-260.
. Schnittman SM, Denning SM, Greenhouse JJ, Justement JS, et al.
Evidence for susceptibility of intrathymic T-cell precursors and their is progeny carrying T-cell antigen receptor phenotypes TCR alpha beta +
and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion. Proc Natl Acad Sci USA 1990b;87(19):7727-31.
Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA. Role of 2o the HTLV-111/LAV envelope in syncytium formation and cytopathicity.
Nature 1986;322(6078):470-4.
Stanley SK, Kessler SW, Justement JS, Schnittman SM, et al. CD34+
bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 1992;149(2):689-97.
2s . Szabo et al., 1995, Curr. Opinion Struct. Biol., 5(5) : 699-705.
Terai C, Kornbluth RS, Pauza CD, Richman DD, Carson DA.
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 1991;87(5):1710-5.
Valadon P. et al., 1996, J Mol Biol, 261 : 11-22.
Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A., 1998, NKp44, a novel triggering surface molecule specifically expressed by activated natural s killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis, J Exp Med 1998 Jun 15;187(12):2065-72 Wei X, Ghosh SK, Taylor ME, Johnson VA, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
to . Westerink M.A.J., 1995, Proc. Natl. Acad. Sci. USA, 92 : 4021-4025 .
Zagury D, Bernard J, Leonard R, Cheymier R, et af. Long-term cultures of HTLV-III infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986;231(4740):850-3.
is DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST L,E TOME 1 DE 2 NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional valumes please contact the Canadian Patent Office.
Claims (28)
1. A polypeptide comprising the following amino acid sequence X1X2X3X4X5X6SWSNKSX7X8X9X10X11 (I), wherein X1, X2, X3, X5, X6, X7, X9, X10, and X11 mean, independently one from each other, any amino acid residue, X4 means any amino acid residue except A and W, and wherein X8 means any amino acid residue except E and S.
2. The polypeptide according to claim 1, comprising the following amino acid sequence PWASNASWSNKSLDDIW (II).
3. The polypeptide according to claim 1, consisting of the following amino acid sequence :
PWASNASWSNKSLDDIW (II).
PWASNASWSNKSLDDIW (II).
4. A pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family, which comprises an effective amount of a ligand compound which specifically binds to the polypeptide according to anyone of claims 1-3 in combination with at least one physiologically acceptable excipient.
5. The pharmaceutical composition according to claim 4, wherein said ligand compound consists of an antibody directed to the polypeptide according to anyone of claims 1-3.
6. A pharmaceutical composition for treating a cancer, which comprises an effective amount of an antigenic compound comprising or consisting of a polypeptide according to anyone of claims 1-3, in combination with at least one physiologically acceptable excipient.
7. An immunogenic composition comprising a polypeptide according to anyone of claims 1-3, in combination with at least one physiologically acceptable excipient.
8. A vaccine composition comprising a polypeptide according to claims 1-3 and an immunoadjuvant compound.
9. The vaccine composition of claim 8, wherein said antigenic compound comprises from 2 to 12 peptides of formula "SWSNKS".
10. The vaccine composition according to claim 9, wherein said antigenic compound has the following formula (III) :
NH2-PepNt-[(I)n-PepX n]n-PepCt- COOH (III), wherein :
- "PepNt" consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the N-terminal end of the polypeptide of formula (III) ;
- "[(I)n-PepX n]" consists of a polypeptide unit wherein - "(I)1" to - "(I)n" each consists of, one independently from each other, a polypeptide of formula "SWSNKS", with n being an integer from 1 to 12; and - "PepX1" to "PepX n" each consists of, one independently from the other, a spacer polypeptide having an amino acid length varying from 0 to 30 amino acid residues, with n being an integer from 1 to 12;
- n is the number of [(I)n-PepX n] polypeptide units in said polypeptide, with n being an integer from 1 to 12; and - "PepCt" consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the C-terminal end of the polypeptide of formula (III).
NH2-PepNt-[(I)n-PepX n]n-PepCt- COOH (III), wherein :
- "PepNt" consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the N-terminal end of the polypeptide of formula (III) ;
- "[(I)n-PepX n]" consists of a polypeptide unit wherein - "(I)1" to - "(I)n" each consists of, one independently from each other, a polypeptide of formula "SWSNKS", with n being an integer from 1 to 12; and - "PepX1" to "PepX n" each consists of, one independently from the other, a spacer polypeptide having an amino acid length varying from 0 to 30 amino acid residues, with n being an integer from 1 to 12;
- n is the number of [(I)n-PepX n] polypeptide units in said polypeptide, with n being an integer from 1 to 12; and - "PepCt" consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the C-terminal end of the polypeptide of formula (III).
11. The vaccine composition according to anyone of claims 8-10 wherein the immunoadjuvant compound is selected in the group consisting of Freund complete adjuvant, Freund incomplete adjuvant, aluminium hydroxide, calcium phosphate, aluminium phosphate, potassium phosphate, Cholera toxin (CT) and its B subunit (CTB), toxins from Bordetella pertusssis (PT), labile toxin (LT) from Escherichia coli, monophosphoryl lipid A, CpG oligonucleotides, imidazoquinolones, oil in water emulsions comprising squalene and synthetic copolymers, muramyl dipeptides and their derivatives, saponins and immunostimulating complexes (ISCOMs), and dimethyldioctadecylammonium bromide or chloride (DDA).
12. The vaccine composition according to anyone of claims 8-11, wherein said antigenic compound is covalently linked through an amino acid residue to a carrier protein or to a synthetic polymer.
13. The vaccine composition according to claim 12, wherein said carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin, or diphtheria toxoid.
14. The vaccine composition according to claim 12, wherein said synthetic polymer is a multiple branch peptide construction comprising a core matrix comprised of lysine residues.
15. The vaccine composition according to anyone of claims 11-13 wherein there is a spacer between said polypeptide and said carrier protein or synthetic polymer.
16 A vaccine composition comprising a polypeptide comprising the amino acid sequence SWSNKS, said polypeptide being covalently linked through an amino acid residue to a carrier protein or to a synthetic polymer.
17 The vaccine composition according to claim 16, wherein said carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin, or diphtheria toxoid.
18 The vaccine composition according to claim 15, wherein said synthetic polymer is a multiple branch peptide construction comprising a core matrix comprised of lysine residues.
19 The vaccine composition according to claims 16-18 wherein there are spacers between said polypeptide and said carrier protein or synthetic polymer.
20 A method for the in vitro screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV
virus, wherein said method comprises the steps of :
(i) incubating a candidate compound to be tested with a polypeptide according to anyone of claims 1-3, (ii) assaying for the binding of the candidate compound to be tested with a polypeptide according to anyone of claims 1-3.
virus, wherein said method comprises the steps of :
(i) incubating a candidate compound to be tested with a polypeptide according to anyone of claims 1-3, (ii) assaying for the binding of the candidate compound to be tested with a polypeptide according to anyone of claims 1-3.
21. The method according to claim 20, wherein step (ii) consists of subjecting to a gel migration assay the mixture obtained at the end of step (i) and detecting the complexes formed between the candidate compound and a polypeptide according to anyone of claims 1-3.
22. A method for the in vitro screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV
virus, wherein said method comprises the steps of :
a) (i) bringing into contact a first CD4+ T-cell culture with a candidate compound, and HIV virus ;
(ii) bringing into contact a second CD4+ T-cell culture with HIV virus, in the absence of said candidate compound ; and b) detecting the presence of NKp44L at the CD4+ T-cells surface issued from the culture (i) and (ii).
virus, wherein said method comprises the steps of :
a) (i) bringing into contact a first CD4+ T-cell culture with a candidate compound, and HIV virus ;
(ii) bringing into contact a second CD4+ T-cell culture with HIV virus, in the absence of said candidate compound ; and b) detecting the presence of NKp44L at the CD4+ T-cells surface issued from the culture (i) and (ii).
23. The method according to claim 22, comprising an additional step (c) which consists of selecting positively the candidate compound as a therapeutical agent when the level of expression of NKp44L at the CD4+
T-cells surface issued from the culture (ii) is higher than the level of expression of NKp44L at the CD4+ T-cells surface issued from the culture (i).
T-cells surface issued from the culture (ii) is higher than the level of expression of NKp44L at the CD4+ T-cells surface issued from the culture (i).
24 A method for the in vitro screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV
virus, wherein said method comprises the steps of :
(i) submitting a candidate compound to a screening method according to anyone of claims 20 and 21, and (ii) submitting a candidate compound positively selectionned at step (i) to the screening method according to anyone of claim 22 and 23.
virus, wherein said method comprises the steps of :
(i) submitting a candidate compound to a screening method according to anyone of claims 20 and 21, and (ii) submitting a candidate compound positively selectionned at step (i) to the screening method according to anyone of claim 22 and 23.
25 A method for the in vitro assessment of the progression status of the infection of an individual with an HIV virus, wherein said method comprises the step of detecting in a sample from said individual, antibodies directed against a polypeptide according to anyone of claims 1-3.
26 The use of a ligand compound which specifically binds to the polypeptide according to anyone of claims 1-3, for manufacturing a pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family.
27 The use of a polypeptide according to anyone of claims 1-3, for manufacturing a vaccine composition for treating a disease linked to the infection of an individual with a virus of the HIV family.
28 An antibody directed against a polypeptide according to claims 1-3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2004/001106 WO2004070385A1 (en) | 2003-02-06 | 2004-02-06 | A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual |
EPPCT/EP2004/01106 | 2004-02-06 | ||
PCT/EP2005/001395 WO2005076001A2 (en) | 2004-02-06 | 2005-02-07 | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2558733A1 true CA2558733A1 (en) | 2005-08-18 |
CA2558733C CA2558733C (en) | 2016-04-19 |
Family
ID=34833870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2558733A Expired - Fee Related CA2558733C (en) | 2004-02-06 | 2005-02-07 | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1954217B (en) |
CA (1) | CA2558733C (en) |
WO (1) | WO2005076001A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010040853A1 (en) * | 2008-10-10 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method |
ES2558933T3 (en) | 2009-01-29 | 2016-02-09 | Michel Vandevelde | Composition of a vaccine based on a virus that has a protein with one or several zinc finger residues, its preparation procedure and its use |
CN102532280A (en) * | 2010-12-08 | 2012-07-04 | 吉林大学 | HIV (human immunodeficiency virus) immunogen and preparation thereof |
WO2016184962A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
EP3522917A2 (en) | 2016-10-07 | 2019-08-14 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
KR20240007316A (en) * | 2016-10-07 | 2024-01-16 | 엔터롬 에스.에이. | Immunogenic compounds for cancer therapy |
CN114397460B (en) * | 2021-12-09 | 2022-11-11 | 华南理工大学 | Biomarker storage solution and biomarker reagent |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1108820C (en) * | 1999-11-12 | 2003-05-21 | 清华大学 | Preparation of epitope vaccine with single monoepitope or multiple monoepitope duplication |
IL137419A0 (en) * | 2000-07-20 | 2001-07-24 | Yissum Res Dev Co | Nk cells activating receptors and their therapeutic and diagnostic uses |
CN1339320A (en) * | 2000-08-18 | 2002-03-13 | 清华大学 | AIDS vacuum and its preparing method and use |
PT1368478E (en) * | 2001-01-05 | 2006-07-31 | Sanofi Pasteur | POLIPEPTIDO INDUCTOR OF HIV NEUTRALIZING ANTIBODIES |
-
2005
- 2005-02-07 CA CA2558733A patent/CA2558733C/en not_active Expired - Fee Related
- 2005-02-07 CN CN2005800108157A patent/CN1954217B/en not_active Expired - Fee Related
- 2005-02-07 WO PCT/EP2005/001395 patent/WO2005076001A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2005076001A3 (en) | 2005-11-24 |
WO2005076001A2 (en) | 2005-08-18 |
CA2558733C (en) | 2016-04-19 |
CN1954217A (en) | 2007-04-25 |
CN1954217B (en) | 2013-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2558733C (en) | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual | |
Fantini et al. | Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. | |
Boudet et al. | Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. | |
Haigwood et al. | Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile | |
Gougeon et al. | Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. | |
EP1152012B1 (en) | CD8 based vaccine against tuberculosis | |
Nardelli et al. | CD4+ blood lymphocytes are rapidly killed in vitro by contact with autologous human immunodeficiency virus-infected cells. | |
US6024965A (en) | Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection | |
CA2224003C (en) | Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell | |
EP0609305A1 (en) | Type c-like human retrovirus linked to multiple sclerosis (ms) | |
US20090136533A1 (en) | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL | |
Schneider-Schaulies et al. | Receptor (CD46) modulation and complement-mediated lysis of uninfected cells after contact with measles virus-infected cells | |
US5843635A (en) | Inhibition of APC-mediated apoptosis of activated T lymphocytes | |
Jacotot et al. | HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells | |
Sherman et al. | Identification of human T cell leukemia/lymphoma virus type I antibodies, DNA, and protein in patients with polymyositis | |
Kameoka et al. | Protease-defective, gp120-containing human immunodeficiency virus type 1 particles induce apoptosis more efficiently than does wild-type virus or recombinant gp120 protein in healthy donor-derived peripheral blood T cells | |
CN103687875B (en) | The compositions that prevention and/or treatment HIV-1 virus infect | |
US20170128564A1 (en) | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL | |
US20070092525A1 (en) | Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual | |
EP1714153A2 (en) | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual | |
WO2010040853A1 (en) | A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method | |
Margolin et al. | High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys | |
JPH09510603A (en) | Method for using a resonance energy transfer-based assay for HIV-1 envelope glycoprotein mediated membrane fusion, and kits for performing same | |
VIEILLARD et al. | Sommaire du brevet 2519012 | |
Uchiyama et al. | Fas ligand-mediated depletion of CD4 and CD8 lymphocytesby monomeric HIV-1-gp120 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190207 |